Data / Research funding / Sickle Cell Disease
Sickle Cell Disease: 436 NIH awards ($553.7M) to 144 organizations
436 NIH awards ($553.7M) in the NIH spending category Sickle Cell Disease, to 144 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
436 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Cure Sickle Cell | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $19,980,036 | September 28, 2018 | September 30, 2026 | EAPEN, MARY | reporter.nih.gov |
| Immune signatures of vaccine responses in vulnerable populations | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,275,325 | July 12, 2010 | April 30, 2028 | MONTGOMERY, RUTH R | reporter.nih.gov |
| CURE SICKLE CELL INITIATIVE DATA STRATEGY AND DATA RESOURCES PROGRAM | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $13,440,748 | September 28, 2018 | December 31, 2026 | KRONER, BARBARA L | reporter.nih.gov |
| Sickle Cell Disease and Cardiovascular Risk- Red Cell Exchange SCD-CARRE | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $9,739,425 | September 1, 2022 | April 30, 2027 | GLADWIN, MARK T | reporter.nih.gov |
| "REAL Answers" (Registry Expansion Analyses to Learn) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $7,362,213 | August 20, 2023 | July 31, 2028 | GLASSBERG, JEFFREY AVINS | reporter.nih.gov |
| Sickle Cell Disease Cure Initiative (SCDC) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $7,000,926 | September 30, 2017 | June 30, 2026 | COLEMAN-COWGER, VICTORIA HOPE | reporter.nih.gov |
| 1/2 Sickel Cell Disease Treatment with Arginine Therapy (STArT Trial) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,920,555 | September 20, 2020 | August 31, 2026 | MORRIS, CLAUDIA R | reporter.nih.gov |
| Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,498,374 | August 1, 2017 | July 31, 2027 | WARE, RUSSELL E | reporter.nih.gov |
| Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain | NIH | National Center for Complementary & Integrative Health | 2021 to 2024 | $6,352,490 | September 21, 2020 | August 31, 2025 | DOORENBOS, ARDITH Z | reporter.nih.gov |
| Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $5,977,497 | August 15, 2022 | July 31, 2027 | KANTER, JULIE | reporter.nih.gov |
| CureSC Manufacturing Resource Platform | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $5,179,238 | September 27, 2019 | September 30, 2026 | CARDOSO, ANGELO A. | reporter.nih.gov |
| Novel Strategies to Improve Blood Transfusion Practice | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $5,119,758 | August 15, 2022 | July 31, 2027 | LUO, HONGBO R | reporter.nih.gov |
| Sickle Africa Data Coordinating Center | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,779,335 | April 1, 2017 | April 30, 2027 | WONKAM, AMBROISE | reporter.nih.gov |
| Molecular and Translational Studies in Hematologic Disorders | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $4,297,096 | March 15, 2019 | February 28, 2025 | LOPEZ, JOSE ARON | reporter.nih.gov |
| The Role of the MBD2-NuRD Complex in Gamma-Globin Gene Silencing | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $4,278,408 | August 1, 2018 | August 31, 2029 | GINDER, GORDON D | reporter.nih.gov |
| Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,065,243 | March 15, 2021 | February 28, 2027 | DEBAUN, MICHAEL R. | reporter.nih.gov |
| Integrative Training Program for Pediatric Sickle Cell Pain | NIH | National Center for Complementary & Integrative Health | 2024 | $4,030,343 | September 19, 2022 | August 31, 2027 | SIL, SOUMITRI | reporter.nih.gov |
| Base editing and prime editing for sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,000,055 | January 1, 2021 | June 30, 2030 | WEISS, MITCHELL J | reporter.nih.gov |
| Engineering biophysical microtechnologies for hematologic applications in health and disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,836,413 | March 22, 2019 | February 28, 2027 | LAM, WILBUR A | reporter.nih.gov |
| 2/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,771,268 | May 15, 2019 | April 30, 2027 | BROOKS, MARIA MORI | reporter.nih.gov |
| Basic and Translational Studies in Redox Regulation of Cardiovascular Physiology and Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,766,063 | January 1, 2022 | December 31, 2028 | STRAUB, ADAM CARL | reporter.nih.gov |
| Peer suppoRt for adolescents and Emerging adults with Sickle cell pain: promoting ENgagement in Cognitive behavioral thErapy | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $3,735,563 | August 10, 2023 | July 31, 2028 | ROLLMAN, BRUCE LAWRENCE | reporter.nih.gov |
| Novel therapeutic gene editing to induce fetal hemoglobin for sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,710,340 | September 1, 2023 | August 31, 2028 | WEISS, MITCHELL J | reporter.nih.gov |
| Minocycline as a potential therapy for neuroinflammation and cognitive deficit in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,659,814 | December 15, 2020 | November 30, 2026 | HYACINTH, HYACINTH IDU | reporter.nih.gov |
| Immune Pathophysiology of Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,589,657 | March 1, 2022 | December 31, 2028 | YAZDANBAKHSH, KARINA | reporter.nih.gov |
| 1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $3,567,710 | May 15, 2019 | August 31, 2022 | GLADWIN, MARK T | reporter.nih.gov |
| Development of a Clinical Hemoglobin Modulator | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $3,473,811 | June 1, 2020 | May 31, 2024 | PERRINE, SUSAN PARK | reporter.nih.gov |
| Regulation of Hemoglobin Switching | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,354,270 | August 5, 2013 | January 31, 2027 | BLOBEL, GERD A | reporter.nih.gov |
| SCD REVIVE - Retina to Evaluate Vaso occlusion In the Vasculature of the Eye | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,242,672 | April 10, 2022 | March 31, 2027 | GLASSBERG, JEFFREY AVINS | reporter.nih.gov |
| Predicting Progression of Chronic Kidney Disease in Sickle Cell Anemia Using Machine Learning Models (PREMIER) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,193,450 | September 10, 2021 | August 31, 2026 | ATAGA, KENNETH I | reporter.nih.gov |
| The Impact of Cerebral Metabolic Stress on the Development of the Structural and Functional Connectome in Pediatric Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,089,102 | April 5, 2021 | March 31, 2027 | FIELDS, MELANIE ERIN | reporter.nih.gov |
| Sulfated Non-Anticoagulant Heparin Nanoparticle (VVP728) for Sickle Cell Disease Management | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $3,058,782 | September 23, 2019 | June 30, 2026 | KORCZAK, BOZENA | reporter.nih.gov |
| CHOICES for Sickle Cell Reproductive Health: RCT of a Preconception Intervention Model for a Single Gene Disorder | NIH | National Human Genome Research Institute | 2021 to 2024 | $3,034,701 | September 1, 2021 | June 30, 2026 | WILKIE, DIANA J | reporter.nih.gov |
| Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $3,033,785 | June 1, 2020 | May 31, 2025 | LEBENSBURGER, JEFFREY D | reporter.nih.gov |
| HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,999,194 | April 7, 2016 | February 28, 2027 | GOMPERTS, EDWARD | reporter.nih.gov |
| Nociceptive Mechanisms Underlying Sickle Cell Pain | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,998,866 | September 30, 2009 | December 31, 2028 | STUCKY, CHERYL LOUISE | reporter.nih.gov |
| Affordable, quantitative, point-of-care microchip-electrophoresis for screening and treatment monitoring of sickle cell disease, thalassemias, and anemias | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,986,386 | September 1, 2018 | February 28, 2026 | GALEN, PETER | reporter.nih.gov |
| Biomarkers of ischemic brain injury in adults with sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,834,684 | February 15, 2022 | January 31, 2027 | JORDAN, LORI CHAFFIN | reporter.nih.gov |
| Production of Cultured Red Blood Cells | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,816,822 | September 15, 2015 | March 31, 2029 | BOUHASSIRA, ERIC E. | reporter.nih.gov |
| 2/2: Sickle Cell Disease Treatment with Arginine Therapy (STArT) trial | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,796,573 | September 20, 2020 | August 31, 2026 | CASPER, THERON C | reporter.nih.gov |
| Sickle Pan-African Research Consortium Clinical Coordinating Center (SPARCO Center) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,772,178 | April 1, 2017 | April 30, 2027 | MAKANI, JULIE | reporter.nih.gov |
| EXERCISE OPTION PERIOD 2 FOR BPA ORDER TITLED "CONTENT DEVELOPMENT AND GRAPHIC/MEDICAL ARTS, IMAGING, AND BRAND MANAGEMENT" AGAINST THE NHLBI OSPEEC B | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $2,748,495 | September 15, 2020 | March 14, 2024 | PISONE, THUY | reporter.nih.gov |
| Sickle Cell Disease and Sickle Cell Trait Protection Against HIV-1-infection in Africans and African Americans | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,746,146 | May 5, 2014 | February 28, 2026 | NEKHAI, SERGEI | reporter.nih.gov |
| The paradoxical response to iron in pulmonary hypertension of sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,709,179 | February 1, 2022 | January 31, 2027 | IRWIN, DAVID CHARLES | reporter.nih.gov |
| PET Imaging of Vaso-Occlussive Crisis in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,679,004 | March 15, 2022 | February 28, 2027 | NOVELLI, ENRICO M | reporter.nih.gov |
| MR-Derived Cerebral Oxygen Metabolism underlying Ischemic Vulnerability in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,672,673 | August 15, 2015 | June 30, 2025 | FORD, ANDRIA LEE | reporter.nih.gov |
| Mechanism of sickle cell disease-specific venous thromboembolism | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,643,179 | April 1, 2021 | March 31, 2025 | PAWLINSKI, RAFAL L | reporter.nih.gov |
| Molecular mechanism and targeting of chronic pain in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,632,365 | January 16, 2018 | January 31, 2025 | WANG, ZAIJIE JIM | reporter.nih.gov |
| In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia and Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,618,613 | June 1, 2016 | July 31, 2025 | LIEBER, ANDRE MICHAEL | reporter.nih.gov |
| Digital twins of the spleen to accelerate the design and development of new therapies in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,618,565 | August 19, 2020 | December 31, 2028 | KARNIADAKIS, GEORGE | reporter.nih.gov |
| Transforming Exercise Testing and Physical Activity Assessment in Children: New Approaches to Advance Clinical Translational Research in Child Health | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $2,614,587 | July 17, 2018 | June 30, 2025 | COOPER, DAN M | reporter.nih.gov |
| Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $2,611,866 | March 5, 2023 | February 28, 2026 | JOHN PADERI, JOHN PADERI JOHN PADERI | reporter.nih.gov |
| Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,608,434 | May 15, 2020 | April 30, 2026 | WALTER, ROLAND BRUNO | reporter.nih.gov |
| A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $2,589,070 | September 18, 2023 | August 31, 2025 | JOHN PADERI, JOHN PADERI JOHN PADERI | reporter.nih.gov |
| Sickle Cell Improvement: ENhancing Care in the Emergency Department (SCIENCE) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,561,602 | September 1, 2021 | July 31, 2027 | BROUSSEAU, DAVID C | reporter.nih.gov |
| Developing a multiscale understanding of biophysical processes in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,540,505 | September 1, 2017 | May 31, 2025 | WOOD, DAVID KEVIN | reporter.nih.gov |
| Improving transfusion therapy for patients with sickle cell disease with pluripotent stem cell-derived red cells | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,528,360 | September 15, 2016 | May 31, 2025 | CHOU, STELLA T | reporter.nih.gov |
| Systematic Genetic Dissection of Human Erythropoiesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,486,216 | September 20, 2014 | May 31, 2029 | SANKARAN, VIJAY GANESH | reporter.nih.gov |
| Single-cell measurement of cyclic stress on sickle blood cells by imaging-microfluidics | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,434,947 | May 1, 2021 | April 30, 2026 | SO, PETER T. | reporter.nih.gov |
| Transfusion-driven hyperhemolysis in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,430,616 | September 1, 2023 | June 30, 2027 | AN, XIULI | reporter.nih.gov |
| Pathways for innovation in Blood Transfusión Systems in Kenya (PITS Kenya) | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,422,222 | July 1, 2020 | June 30, 2027 | KIVULI, TECLA CHELAGAT | reporter.nih.gov |
| A Stress and Pain Self-management m-Health App for Adult Outpatients with Sickle Cell Disease | NIH | National Institute of Nursing Research | 2021 to 2024 | $2,402,223 | September 7, 2020 | June 30, 2026 | EZENWA, MIRIAM OMELEBELE | reporter.nih.gov |
| Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,393,906 | August 15, 2020 | August 31, 2027 | LIGHT, DAVID RICHARD | reporter.nih.gov |
| The role of metabolic and hemodynamic reserve in age-related brain vulnerability in pediatric sickle cell anemia | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,388,937 | June 15, 2021 | March 31, 2027 | GUILLIAMS, KRISTIN | reporter.nih.gov |
| Vascular Targeting Genomic & Genetic Strategies for Acute Chest Syndrome | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,381,226 | February 5, 2013 | October 31, 2025 | MACHADO, ROBERTO F. | reporter.nih.gov |
| Clonal hematopoiesis and inherited genetic variation in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,361,205 | April 1, 2023 | March 31, 2027 | BICK, ALEXANDER | reporter.nih.gov |
| Omics, mice and men: Development of precision transfusion medicine | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,341,220 | September 18, 2009 | July 31, 2028 | GLADWIN, MARK T | reporter.nih.gov |
| Chemotherapy-free cure of hemoglobin disorders through base editing | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,334,252 | September 1, 2023 | May 31, 2027 | BAUER, DANIEL EVAN | reporter.nih.gov |
| Phase I study of panobinostat in adults with sickle cell disease: novel approach to recruitment and retention | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,275,984 | February 15, 2023 | January 31, 2027 | KUTLAR, ABDULLAH | reporter.nih.gov |
| Artery biomechanics and vascular damage in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,274,529 | May 1, 2021 | April 30, 2026 | BOTCHWEY, EDWARD A. | reporter.nih.gov |
| Multiplex base/prime editors for in vivo selection of modified HSPCs in hemoglobinopathy | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $2,218,334 | January 17, 2017 | December 31, 2025 | KIEM, HANS-PETER | reporter.nih.gov |
| Etiology of Persistent Microalbuminuria in Nigeria | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,202,068 | July 1, 2021 | May 31, 2026 | WESTER, C. WILLIAM | reporter.nih.gov |
| In vivo mechanisms mediating sickle cell vaso-occlusion and organ damage | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,197,616 | September 30, 2001 | August 31, 2025 | KELLY, LIBUSHA | reporter.nih.gov |
| Mechanisms of Inflammation in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,190,731 | April 1, 2016 | March 31, 2026 | PRITCHARD, KIRKWOOD ARTHUR | reporter.nih.gov |
| Long-Acting, Short-Residing Nanochelators for Iron Overload Therapy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,154,309 | January 1, 2023 | December 31, 2026 | CHOI, HAK SOO | reporter.nih.gov |
| Role of Xanthine Oxidase in Heme-induced Vascular Dysfunction | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,141,034 | May 1, 2021 | February 28, 2025 | STRAUB, ADAM CARL | reporter.nih.gov |
| Role of FGF23 in Bone, Kidney, Blood, Crosstalk in Sickle Cell Disease Mice | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,133,643 | April 1, 2022 | January 31, 2027 | HURLEY, MARJA MARIE | reporter.nih.gov |
| Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability (Administrative Supplement) | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $2,132,042 | April 15, 2023 | April 30, 2025 | FEDERICI, CHIARA | reporter.nih.gov |
| Investigating hematopoietic stem cell dysfunction during sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,111,564 | April 1, 2023 | March 31, 2027 | MCKINNEY-FREEMAN, SHANNON L | reporter.nih.gov |
| Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $2,111,258 | September 1, 2022 | August 31, 2024 | GOMPERTS, EDWARD | reporter.nih.gov |
| A socio-ecological approach for improving self-management in adolescents with SCD | NIH | National Institute of Nursing Research | 2023 to 2025 | $2,087,021 | September 25, 2023 | June 30, 2028 | CROSBY, LORI E | reporter.nih.gov |
| Pulmonary arteriole occlusion by platelet-neutrophil micro-emboli in Acute Chest Syndrome | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,061,301 | August 15, 2015 | June 30, 2027 | SUNDD, PRITHU | reporter.nih.gov |
| Deciphering unintended large gene modifications in gene editing for sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,057,558 | July 1, 2023 | June 30, 2027 | BAO, GANG | reporter.nih.gov |
| mAnaging siCkle CELl disease through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,055,435 | August 15, 2023 | July 31, 2028 | PEPRAH, EMMANUEL K | reporter.nih.gov |
| Therapeutic Targets in Acute Chest Syndrome | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $2,050,312 | February 7, 2022 | January 31, 2026 | OFORI-ACQUAH, SOLOMON FIIFI | reporter.nih.gov |
| Targeted conditioning to maximize prenatal HSC engraftment for SCD | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,044,659 | July 1, 2023 | June 30, 2027 | ALMEIDA-PORADA, GRACA DUARTE | reporter.nih.gov |
| Diffuse optical spectroscopies to assess cerebral hemodynamics in pediatric sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,025,763 | January 1, 2021 | December 31, 2025 | BUCKLEY, ERIN MCGUIRE | reporter.nih.gov |
| Targeting ZNF410 for HbF reactivation | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,023,010 | March 1, 2023 | February 28, 2027 | BAUER, DANIEL EVAN | reporter.nih.gov |
| Mechanisms of cerebral infarcts and brain oxygen utilization in anemia | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,000,014 | April 1, 2022 | March 31, 2027 | DONAHUE, MANUS J | reporter.nih.gov |
| Isochoric Pressure Based Preservation of Ovarian Tissue | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $1,958,572 | September 26, 2016 | September 30, 2023 | WEEGMAN, BRADLEY P | reporter.nih.gov |
| Endothelialized microfluidic assays for emerging therapies in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,951,527 | April 5, 2022 | March 31, 2024 | FEDERICI, CHIARA | reporter.nih.gov |
| Biased PAR1 Agonism in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,943,750 | January 10, 2021 | December 31, 2026 | SPARKENBAUGH, ERICA M | reporter.nih.gov |
| Development and validation of novel mouse models and expression vectors for characterizing severe alpha-thalassemia pathophysiology and evaluating gene therapy approaches. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,927,121 | June 1, 2023 | May 31, 2027 | RIVELLA, STEFANO | reporter.nih.gov |
| ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,904,006 | September 15, 2023 | August 31, 2026 | SEIGUER, SEBASTIAN | reporter.nih.gov |
| Sickle Cell Disease Pain Analgesia And Integrative Network | NIH | National Center for Complementary & Integrative Health | 2024 to 2025 | $1,893,837 | September 5, 2024 | August 31, 2029 | GUPTA, KALPNA | reporter.nih.gov |
| Renal endothelium and the development of chronic kidney disease in sickle cell disorders | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,888,544 | March 15, 2023 | January 31, 2027 | GHOSH, SAMIT | reporter.nih.gov |
| Cilia as a biomarker of CNS vascular health | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,882,292 | September 3, 2020 | August 31, 2025 | RAMCHANDRAN, RAMANI | reporter.nih.gov |
| Role of mast cell traps in Alzheimer's disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,880,530 | April 4, 2019 | March 31, 2024 | GUPTA, KALPNA | reporter.nih.gov |
| Public Understanding of Big data in Genomics Medicine in Africa (PUBGEM-Africa) | NIH | National Institute of Mental Health | 2021 to 2025 | $1,853,796 | September 20, 2021 | July 31, 2027 | WONKAM, AMBROISE | reporter.nih.gov |
| Understanding and Addressing the Social Determinants of Health for Families of Children with Sickle Cell Anemia within Pediatric Hematology | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,853,674 | May 16, 2019 | February 29, 2024 | KAVANAGH, PATRICIA L | reporter.nih.gov |
| Measuring Lifelong Multimorbidity with Patient Perspectives: Implementing and Visualizing the Cumulative Burden Methodology Across Cohorts | NIH | National Cancer Institute | 2022 to 2025 | $1,843,355 | March 11, 2022 | February 28, 2026 | BHAKTA, NICKHILL HITESH | reporter.nih.gov |
| HBB gene-editing for treating sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,827,122 | April 17, 2020 | March 31, 2024 | BAO, GANG | reporter.nih.gov |
| A Sample-to-Answer Point-of-Care Diagnostic for Recently Transfused Sickle Cell Anemia Patients in Low Resource Settings | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,824,498 | June 1, 2023 | May 31, 2027 | RICHARDS-KORTUM, REBECCA R. | reporter.nih.gov |
| In vivo hematopoietic stem cell genetic modification by viral particles | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,764,905 | September 9, 2024 | May 31, 2028 | BAUER, DANIEL EVAN | reporter.nih.gov |
| MicroRNA as a Novel Therapeutic Target for Pain in Sickle Cell Disease | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $1,764,145 | August 1, 2025 | July 31, 2029 | HE, YING | reporter.nih.gov |
| Ferroptosis in the Heart: Iron Calcium Crosstalk and Compartmentalization | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,751,600 | December 25, 2021 | November 30, 2026 | XIE, LAI-HUA | reporter.nih.gov |
| Cellular and Molecular Control of Normal and Disordered Erythropoiesis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,741,086 | February 15, 2024 | January 31, 2031 | BLANC, LIONEL | reporter.nih.gov |
| Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,731,315 | September 15, 2021 | May 31, 2027 | MCGANN, PATRICK THOMAS | reporter.nih.gov |
| Portable, affordable, quantitative microchip electrophoresis for hemoglobin A1C testing | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2023 | $1,730,598 | August 20, 2018 | June 30, 2025 | GALEN, PETER | reporter.nih.gov |
| Autoantibody-induced type 1 interferons and RBC alloimmunization in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,670,000 | July 1, 2022 | June 30, 2027 | GIBB, DAVID R | reporter.nih.gov |
| RH genotype matched red cell transfusions for patients with sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,669,618 | August 15, 2019 | July 31, 2025 | CHOU, STELLA T | reporter.nih.gov |
| A precision therapy approach to red cell transfusion for sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,629,998 | May 1, 2024 | April 30, 2029 | CHOU, STELLA T | reporter.nih.gov |
| Developing next generation synthetic nucleic acid analogous for sickle cell disease gene editing | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,610,000 | December 15, 2019 | November 30, 2025 | BAHAL, RAMAN | reporter.nih.gov |
| EXERCISING OPTION PERIOD 2 FOR BPA ORDER TITLED "STRATEGIC COMMUNICATIONS & ENGAGEMENT SUPPORT FOR BLOOD DISEASES AND DISORDERS" AGAINST THE NHLBI OSP | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,599,748 | September 23, 2020 | March 22, 2024 | GEAGHAN, TAYLOR | reporter.nih.gov |
| Pathways of Cell-Free Hemoglobin in Sickle Cell Nephropathy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,599,000 | July 1, 2020 | June 30, 2025 | SARAF, SANTOSH | reporter.nih.gov |
| Implementation and Implications of Sickle Cell Trait Screening in the NCAA | NIH | National Human Genome Research Institute | 2021 to 2023 | $1,584,995 | September 15, 2023 | June 30, 2024 | ROYAL, CHARMAINE DAWN MARIE | reporter.nih.gov |
| Self-Management for Youth Living with Sickle Cell Disease (SMYLS) | NIH | National Institute of Nursing Research | 2023 to 2025 | $1,570,500 | April 21, 2023 | January 31, 2028 | PHILLIPS, SHANNON M. | reporter.nih.gov |
| IMPROVE 2: Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,567,821 | August 1, 2018 | June 30, 2024 | GLASSBERG, JEFFREY AVINS | reporter.nih.gov |
| CD39-carrying extracellular vesicles regulate pulmonary thrombosis in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,552,984 | August 1, 2023 | July 31, 2027 | SUNDD, PRITHU | reporter.nih.gov |
| Mechanisms of platelet exosome-mediated acute chest syndrome in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,545,150 | April 22, 2019 | March 31, 2024 | NOVELLI, ENRICO M | reporter.nih.gov |
| Transcriptomics of Pain in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,540,430 | September 1, 2022 | August 31, 2026 | SHEEHAN, VIVIEN ANDREA | reporter.nih.gov |
| Comparative Study of Haitian and Miami Cohorts of Haitian-American and Haitian Immigrant Children with Sickle Cell Disease (CSHSCD) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,492,725 | September 1, 2019 | June 30, 2025 | ALVAREZ, OFELIA AMPARO | reporter.nih.gov |
| Pulmonary arteriole occlusion by platelet-neutrophil micro-emboli in Acute Chest Syndrome | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,488,171 | August 15, 2015 | August 31, 2023 | SUNDD, PRITHU | reporter.nih.gov |
| Mimicking, Exploiting, and Understanding Biology's Heterogeneity in 4D | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,486,420 | September 15, 2020 | August 31, 2025 | DEFOREST, COLE A | reporter.nih.gov |
| Engineering enhanced erythropoiesis for red blood cell disorders | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,476,000 | September 15, 2025 | August 31, 2028 | CROMER, MICHAEL KYLE | reporter.nih.gov |
| Sickle Pan-African Research Consortium (SPARCO)- Tanzania | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,471,230 | May 15, 2021 | April 30, 2027 | BALANDYA, EMMANUEL | reporter.nih.gov |
| Sickle Cell Improvement: ENhancing Care in the Emergency Department (SCIENCE) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,470,760 | September 1, 2021 | February 28, 2023 | BROUSSEAU, DAVID C | reporter.nih.gov |
| Ghana-SPARCO: Ghana Sickle Pan-African Research Consortium | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,442,972 | May 10, 2021 | April 30, 2027 | SARFO, FRED STEPHEN | reporter.nih.gov |
| Investigating the role of the microbiome and inflammation in acute and chronic pain in patients with sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,437,045 | September 1, 2018 | August 31, 2025 | BRANDOW, AMANDA M | reporter.nih.gov |
| A Modality-Agnostic Potency Assay Enabling Both Ex Vivo and In Vivo Genome Editing Therapeutics for Sickle Cell Disease | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,431,363 | April 28, 2023 | March 31, 2026 | GIANNIKOPOULOS, PETROS | reporter.nih.gov |
| Role of Factor XII in Thrombo-Inflammatory Complications of Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,421,702 | July 15, 2024 | June 30, 2028 | PAWLINSKI, RAFAL L | reporter.nih.gov |
| Mechanisms of venous thrombosis and renal dysfunction in sickle trait | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,418,789 | February 15, 2024 | January 31, 2028 | KEY, NIGEL S. | reporter.nih.gov |
| Generalizing genome editing for rare disease-causing variants | NIH | Office of the Director, National Institutes of Health | 2025 | $1,416,375 | September 18, 2025 | August 31, 2028 | NEWBY, GREGORY A. | reporter.nih.gov |
| OSPEEC BPA TASK AREA 1 ORDER TITLED "STRATEGIC COMMUNICATIONS AND MEDIA RELATIONS" - SUPPLEMENT TO ADD DIR FUNDS FOR ORLOFF VIDEOS | NIH | National Heart, Lung, and Blood Institute | 2023 | $1,403,654 | June 3, 2022 | September 2, 2023 | GEAGHAN, TAYLOR | reporter.nih.gov |
| Point of care diagnostic for sickle cell disease | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2024 | $1,401,940 | September 6, 2024 | July 31, 2026 | WAX, ADAM | reporter.nih.gov |
| Molecular and Cellular Pathogenesis of Kidney Disease in Sickle Cell Disorders | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,401,004 | January 1, 2021 | December 31, 2025 | GHOSH, SAMIT | reporter.nih.gov |
| Stroke Prevention in Nigeria: SPRING 2 | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,400,419 | September 1, 2023 | August 31, 2029 | DEBAUN, MICHAEL R. | reporter.nih.gov |
| Complement in the Pathogenesis of Acute Chest Syndrome | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,391,280 | August 1, 2024 | July 31, 2029 | CHONAT, SATHEESH | reporter.nih.gov |
| The dissection of non-canonical cis-regulatory elements downstream of beta-globin locus in the fetal hemoglobin gene regulation | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,372,419 | September 1, 2023 | July 31, 2028 | ZHANG, XIAOTIAN | reporter.nih.gov |
| Elucidating T Cell Ferroptosis in Renal Medullary Carcinoma: 3D Genome Architecture Rewiring and Therapeutic Alleviation | NIH | National Cancer Institute | 2024 to 2025 | $1,357,965 | August 1, 2024 | July 31, 2029 | YANG, LIUQING | reporter.nih.gov |
| Inflammatory caspase activation in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,346,582 | April 1, 2024 | March 31, 2028 | BOUCHIER-HAYES, LISA | reporter.nih.gov |
| Integrative Training Program for Pediatric Sickle Cell Pain | NIH | National Center for Complementary & Integrative Health | 2022 | $1,343,529 | September 19, 2022 | August 31, 2024 | SIL, SOUMITRI | reporter.nih.gov |
| Sickle Pan African Research Consortium Nigeria (SPARC-NEt) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,343,048 | June 1, 2021 | May 31, 2027 | NNODU, OBIAGELI EUNICE | reporter.nih.gov |
| Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $1,298,915 | September 11, 2019 | August 31, 2025 | IDRO, RICHARD IWA | reporter.nih.gov |
| Molecular and Translational Studies in Hematologic Disorders | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,276,908 | March 1, 2025 | February 28, 2032 | LOPEZ, JOSE ARON | reporter.nih.gov |
| RBC Effects on Neutrophil Activation and Phenotypes in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,270,486 | August 15, 2024 | July 31, 2029 | LEE, GRACE MING | reporter.nih.gov |
| The Inflammatory Index as a Biomarker for Pain in Patients with Sickle Cell Disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $1,265,359 | September 26, 2019 | July 31, 2025 | BRANDOW, AMANDA M | reporter.nih.gov |
| Highly Specific ZFN-Based HSC Gene Editing Therapies Identified By In Vivo Barcode Nanoparticle Screens and Rationally Designed mRNA | NIH | National Center for Advancing Translational Sciences | 2022 to 2023 | $1,264,949 | September 16, 2019 | August 31, 2024 | DAHLMAN, JAMES | reporter.nih.gov |
| Investigating PUM1 mediated post-transcriptional regulation of human hemoglobin switching and erythropoiesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,242,739 | April 1, 2023 | March 31, 2028 | GNANAPRAGASAM, MERLIN NITHYA | reporter.nih.gov |
| Immune signatures of vaccine responses in children with sickle cell disease | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,228,468 | December 1, 2023 | October 31, 2028 | YILDIRIM, INCI BURCIN | reporter.nih.gov |
| The Role of Erythrocyte Mitochondrial Retention in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,226,487 | December 8, 2020 | April 30, 2025 | RIVERS, ANGELA | reporter.nih.gov |
| Oxidative stress mechanisms regulating gamma-globin gene transcription in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,196,754 | July 1, 2022 | June 30, 2027 | ZENNADI, RAHIMA | reporter.nih.gov |
| 2/2 A comparison of individualized vs. weight based protocols to treat vaso-occlusive episodes in Sickle Cell Disease (COMPARE VOE) | NIH | National Heart, Lung, and Blood Institute | 2021 | $1,195,009 | September 7, 2018 | August 31, 2024 | BARNHART, HUIMAN X | reporter.nih.gov |
| Data Coordinating Center for Sickle Cell Disease Implementation Consortium (SCDIC) | NIH | National Heart, Lung, and Blood Institute | 2021 | $1,191,318 | August 8, 2016 | December 31, 2023 | KRONER, BARBARA L | reporter.nih.gov |
| Nanoscience-Inspired Acoustofluidic Assembly Lines for Gene and Cellular Therapies | NIH | Office of the Director, National Institutes of Health | 2021 to 2023 | $1,170,000 | September 16, 2019 | August 31, 2025 | JONAS, STEVEN JOHN | reporter.nih.gov |
| Malaria variant surface antigen expression and vulnerability to disease in Malian children with Hemoglobin C trait | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,156,266 | July 15, 2019 | June 30, 2025 | TRAVASSOS, MARK A | reporter.nih.gov |
| DEGRADATION OF BCL11A PROTEIN FOR HbF REACTIVATION | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,149,236 | August 7, 2023 | July 31, 2028 | ORKIN, STUART H | reporter.nih.gov |
| Targeted Identification of Dual Acting Antisickling Agents for Sickle Cell Disease Therapy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,135,267 | March 20, 2021 | February 28, 2023 | SAFO, MARTIN K | reporter.nih.gov |
| Development of fetal hemoglobin inducers targeting epigenetic and oxidative stress mechanisms | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,128,308 | April 20, 2020 | March 31, 2025 | PACE, BETTY SUE | reporter.nih.gov |
| Neuroimaging and Neurocognitive Markers of Brain Injury in Young Children with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,119,993 | April 1, 2023 | March 31, 2028 | LANCE, EBONI I | reporter.nih.gov |
| BMT Core - MSK | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,119,450 | September 30, 2001 | June 30, 2031 | PERALES, MIGUEL-ANGEL | reporter.nih.gov |
| Molecular Mechanism and Targeting of Chronic Pain in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,103,783 | February 1, 2025 | January 31, 2032 | WANG, ZAIJIE JIM | reporter.nih.gov |
| Modeling Inter-individual Differences to Address Pain of Sickle cell disease (MIDAS) | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,098,640 | September 18, 2025 | August 31, 2030 | MANWORREN, RENEE | reporter.nih.gov |
| Genetics of kidney disease in diverse populations | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,080,219 | September 22, 2018 | July 31, 2025 | FRANCESCHINI, NORA | reporter.nih.gov |
| Effective Network to advance Scientific Evidence related to Mechanisms of music-Based interventions (ENSEMBLE) | NIH | National Center for Complementary & Integrative Health | 2024 to 2025 | $1,070,254 | July 24, 2024 | August 31, 2028 | DUSEK, JEFFERY A. | reporter.nih.gov |
| Targeting PGC-1a for the treatment of sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,050,000 | July 1, 2022 | May 31, 2026 | CUI, SHUAIYING | reporter.nih.gov |
| Advancing a Holistic Understanding of Variability in Lived Experience with Sickle Cell Pain | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,049,682 | September 18, 2025 | August 31, 2030 | ROYAL, CHARMAINE DAWN MARIE | reporter.nih.gov |
| A Novel Bone Marrow Transplantation Approach for Sickle Cell Disease Using Targeted Marrow Irradiation | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,049,350 | July 1, 2023 | June 30, 2027 | HUI, SUSANTA K | reporter.nih.gov |
| KYC, an inhibitor of sickle cell disease's vicious cycle in vaso-occlusive crisis and pain | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,045,688 | September 22, 2025 | June 30, 2027 | NAYLOR, STEPHEN | reporter.nih.gov |
| Small Molecule Therapeutics for Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,033,503 | February 15, 2023 | January 31, 2027 | ARCHER, DAVID R | reporter.nih.gov |
| Efficacy of Hypoxic Red Blood Cells Processed with the Hemanext ONE® System in Patients with Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,017,232 | September 5, 2025 | August 31, 2028 | OMERT, LAUREL | reporter.nih.gov |
| H3Africa Kidney Disease Research Network- Collaborative Centers | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $1,011,450 | August 15, 2012 | August 31, 2023 | ADU, DWOMOA | reporter.nih.gov |
| OVARIAN RESERVE IN POST-MENARCHAL FEMALES WITH SICKLE CELL ANEMIA | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $997,419 | August 9, 2020 | July 31, 2025 | PECKER, LYDIA | reporter.nih.gov |
| Sickle Pan-African Research Consortium (SPARCO) Uganda: Strengthening Capacity for Clinical Care, Research and Training in Sickle Cell Disease - SCRT Project. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $992,648 | June 1, 2021 | May 31, 2027 | KIGULI, SARAH | reporter.nih.gov |
| A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $982,081 | September 18, 2023 | August 31, 2027 | PADERI, JOHN | reporter.nih.gov |
| Sex and gender influences on inflammation and pain in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $948,303 | September 1, 2024 | July 31, 2028 | ROE, ANDREA | reporter.nih.gov |
| Thiol isomerases and ERO1 alpha in sickle cell vaso-occlusion | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $928,484 | July 15, 2019 | June 30, 2025 | CHO, JAEHYUNG | reporter.nih.gov |
| A feasibility study of alendronate therapy for osteonecrosis of the femoral head in adults with sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $925,439 | September 20, 2021 | August 31, 2026 | ADESINA, OYEBIMPE OLUYEMISI | reporter.nih.gov |
| BMT Core- University of Michigan Core Clinical Consortium for the BMT Clinical Trials Network (BMT CTN) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $919,741 | September 30, 2001 | June 30, 2031 | YANIK, GREGORY A | reporter.nih.gov |
| Telemedicine for Pediatric Sickle Cell Care in Medically Underserved Communities | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $918,894 | May 1, 2021 | April 30, 2026 | JACOB, SEETHAL | reporter.nih.gov |
| Implementation of Medical Homes for Evidence Based Care of Adolescents and Adults with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $911,903 | August 5, 2016 | December 30, 2023 | KUTLAR, ABDULLAH | reporter.nih.gov |
| Heme-induced metabolic stress drives ferroptosis in sickle cell disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $911,680 | September 25, 2023 | August 31, 2026 | ZHU, XINGGUO | reporter.nih.gov |
| Sickle Hemoglobinopathy reseArch in Zimbabwe (SHAZ) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $904,461 | May 20, 2021 | April 30, 2027 | KUONA, PATIENCE | reporter.nih.gov |
| [18F]fluoromannitol: A novel imaging agent to delineate osteomyelitis in sickle cell disease | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $894,735 | February 26, 2025 | January 31, 2029 | NEUMANN, KIEL | reporter.nih.gov |
| Improving Sickle Cell Disease Care in Mali through Engagement with a Pan-African Sickle Cell Disease Network. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $892,318 | May 11, 2021 | April 30, 2027 | GUINDO, ALDIOUMA | reporter.nih.gov |
| Therapeutic BCL11A enhancer gene editing to induce fetal hemoglobin in β-hemoglobinopathy patients | NIH | National Heart, Lung, and Blood Institute | 2021 | $886,788 | June 18, 2020 | November 30, 2022 | BAUER, DANIEL EVAN | reporter.nih.gov |
| Molecular Analysis of Normal and Thalassemic DNA | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $885,000 | April 1, 1982 | April 30, 2024 | ORKIN, STUART H | reporter.nih.gov |
| DISPLACE: Dissemination and Implementation of Stroke Prevention Looking at the Care Environment | NIH | National Heart, Lung, and Blood Institute | 2021 | $860,336 | August 1, 2017 | June 30, 2023 | KANTER, JULIE | reporter.nih.gov |
| A randomized double-blind, placebo-controlled phase 2 clinical trial of intravenous citrulline for vaso-occlusive crisis in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $859,704 | May 1, 2025 | April 30, 2029 | MAJUMDAR, SUVANKAR | reporter.nih.gov |
| Pre-trial implementation study for ketamine in sickle cell disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $855,305 | September 15, 2022 | August 14, 2023 | LIMKAKENG, ALEXANDER TAN | reporter.nih.gov |
| CRISPR-based transistors for high throughput multiplexed monitoring of CRISPR-based editing efficiency for Sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $854,053 | January 19, 2024 | February 28, 2027 | ARAN, KIANA | reporter.nih.gov |
| Cellular Signaling Pathways in the Regulation of Fetal Hemoglobin for Treatment of Sickle Cell Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $835,800 | July 1, 2021 | March 31, 2026 | PESLAK, SCOTT ALAN | reporter.nih.gov |
| Peer suppoRt for adolescents and Emerging adults with Sickle cell pain: promoting ENgagement in Cognitive behavioral thErapy | NIH | National Heart, Lung, and Blood Institute | 2023 | $819,155 | August 10, 2023 | July 31, 2024 | JONASSAINT, CHARLES RICHARD | reporter.nih.gov |
| CRISPR-based transistors for high throughput multiplexed monitoring of CRISPR-based editing efficiency for Sickle cells disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $814,602 | January 7, 2022 | November 1, 2023 | ARAN, KIANA | reporter.nih.gov |
| Stroke and Cardiovascular Research Training (SCaRT) Institute | NIH | Fogarty International Center | 2021 to 2023 | $811,739 | September 5, 2011 | May 31, 2025 | OGEDEGBE, OLUGBENGA G. | reporter.nih.gov |
| Multiplex base/prime editors for in vivo selection of modified HSPCs in hemoglobinopathy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $810,459 | January 17, 2017 | March 31, 2022 | KIEM, HANS-PETER | reporter.nih.gov |
| Mechanism of cerebral vaculopathy and stroke in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $810,000 | August 16, 2017 | June 30, 2023 | HYACINTH, HYACINTH IDU | reporter.nih.gov |
| Transfusion-driven hyperhemolysis in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2022 | $804,000 | September 13, 2022 | August 31, 2023 | AN, XIULI | reporter.nih.gov |
| Molecular determinants of anti-RBC alloantibody evanescence | NIH | National Heart, Lung, and Blood Institute | 2022 | $798,296 | September 13, 2022 | October 31, 2023 | LUCKEY, CHANCE MARION JOHN | reporter.nih.gov |
| SMILE (Sickle Cell Disease Microbiologic and Immunologic Links to Health) | NIH | National Heart, Lung, and Blood Institute | 2025 | $794,661 | September 19, 2025 | June 30, 2030 | KOPP, BENJAMIN T | reporter.nih.gov |
| Regulation of hemoglobin production in normal and disease states | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $793,140 | July 1, 2021 | June 30, 2026 | KHANDROS, EUGENE | reporter.nih.gov |
| CD39-carrying extracellular vesicles regulate pulmonary thrombosis in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2023 | $789,466 | August 1, 2023 | August 31, 2023 | SUNDD, PRITHU | reporter.nih.gov |
| Patient-Oriented Research in Arginine Deficiency Syndromes | NIH | National Center for Complementary & Integrative Health | 2021 to 2025 | $786,739 | September 24, 2018 | July 31, 2028 | MORRIS, CLAUDIA R | reporter.nih.gov |
| A randomized double-blind, placebo-controlled phase 2 clinical trial of intravenous citrulline for vaso-occlusive crisis in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2024 | $776,011 | March 1, 2024 | December 31, 2024 | MAJUMDAR, SUVANKAR | reporter.nih.gov |
| Dronabinol for the reduction of chronic pain and inflammation in people with sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $773,104 | June 1, 2022 | May 31, 2027 | CURTIS, SUSANNA | reporter.nih.gov |
| The role of HGFL in the sickle cell disease nephropathy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $772,500 | September 19, 2019 | July 31, 2025 | JEREBTSOVA, MARINA A | reporter.nih.gov |
| Chemical tools for modulating the fetal hemoglobin inducer BCL11A | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $772,000 | July 1, 2024 | April 30, 2028 | DASSAMA, LAURA | reporter.nih.gov |
| Delivering Patient-Facing Evidence-Based Guidelines through mHealth to Adults with Sickle Cell Disease (PF-Guide) | NIH | National Heart, Lung, and Blood Institute | 2025 | $765,931 | August 22, 2025 | July 31, 2030 | CRONIN, ROBERT M | reporter.nih.gov |
| Targeted protein degraders for the treatment of b-hemoglobinopathies | NIH | National Heart, Lung, and Blood Institute | 2025 | $765,622 | January 1, 2025 | November 30, 2028 | CREWS, CRAIG M | reporter.nih.gov |
| Hypoxemia with Sleep in Sickle Cell Anemia-Prevalence, Clinical and Cellular Impact & Response to Therapy: A Multi-Site Prospective Study Accessing New Collaborative Pathways | NIH | National Heart, Lung, and Blood Institute | 2025 | $761,028 | September 15, 2025 | June 30, 2029 | LITTLE, JANE | reporter.nih.gov |
| Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using SGLT2 Inhibitors | NIH | National Heart, Lung, and Blood Institute | 2025 | $755,853 | September 15, 2025 | June 30, 2030 | SARAF, SANTOSH | reporter.nih.gov |
| New York City Sickle Cell Implementation Science Consortium | NIH | National Heart, Lung, and Blood Institute | 2021 | $753,289 | August 5, 2016 | June 30, 2023 | RICHARDSON, LYNNE D. | reporter.nih.gov |
| The Role of Endothelin-1 in Tubular Injury in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $747,000 | July 1, 2021 | December 31, 2024 | KASZTAN, MALGORZATA | reporter.nih.gov |
| Sickle cell disease gut dysbiosis effects on CNS pain processing | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $746,997 | February 1, 2023 | January 31, 2026 | SADLER, KATELYN | reporter.nih.gov |
| Enhancing Research capacity for Sickle Cell Disease and related NCDs across the Lifespan in Uganda. ''Enrich Project'' | NIH | Fogarty International Center | 2023 to 2025 | $737,584 | April 1, 2023 | February 29, 2028 | KIGULI, SARAH | reporter.nih.gov |
| Integrative Medicine for Pain Management in Sickle Cell Disease | NIH | National Center for Complementary & Integrative Health | 2021 to 2023 | $734,872 | July 17, 2018 | August 31, 2025 | WANG, YING | reporter.nih.gov |
| Highly Specific ZFN-Based HSC Gene Editing Therapies Identified By In Vivo Barcode Nanoparticle Screens And Rationally Designed Mrna | NIH | National Center for Advancing Translational Sciences | 2021 | $733,169 | September 16, 2019 | September 14, 2022 | DAHLMAN, JAMES | reporter.nih.gov |
| Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $728,111 | September 1, 2022 | August 31, 2027 | GOMPERTS, EDWARD | reporter.nih.gov |
| Redefining Clinical Viscosity in Sickle Cell Diseaseby Leveraging Microfluidic Technologies | NIH | National Heart, Lung, and Blood Institute | 2021 | $719,801 | September 1, 2018 | August 31, 2023 | LAM, WILBUR A | reporter.nih.gov |
| Modeling oxygen-dependent hemoglobin polymerization in sickle cell disease at the single cell level | NIH | National Heart, Lung, and Blood Institute | 2025 | $719,128 | August 15, 2025 | May 31, 2029 | HIGGINS, JOHN MATTHEW | reporter.nih.gov |
| Development and Evaluation of an Information Management and Communication System for Population-wide Point-of-Care Infant Sickle Cell Disease Screening. | NIH | Fogarty International Center | 2023 to 2025 | $713,752 | August 16, 2021 | April 30, 2026 | SEWANKAMBO, NELSON K | reporter.nih.gov |
| Improving Sickle cell care in Adolescents & Adults in Chicago (ISAAC) | NIH | National Heart, Lung, and Blood Institute | 2021 | $699,063 | August 5, 2016 | June 30, 2022 | GORDEUK, VICTOR R | reporter.nih.gov |
| The Implementation of Cognitive Screening and Educational Support to Improve Outcomes of Adolescents and Young Adults with Sickle Cell Disease: From Clinic to the Community and Back | NIH | National Heart, Lung, and Blood Institute | 2021 | $689,703 | August 5, 2016 | June 30, 2024 | KING, ALLISON A | reporter.nih.gov |
| Genetic modifiers of Sickle Cell Kidney Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $682,139 | February 1, 2022 | January 31, 2027 | ZAHR, RIMA | reporter.nih.gov |
| Kinetics of Red Blood Cell Clearance in Chronically Transfused Children with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $681,844 | May 3, 2020 | April 30, 2025 | YEE, MARIANNE ELAINE MCPHERSON | reporter.nih.gov |
| Promotion of Exclusive Breastfeeding in Children with Sickle Cell Disease for Improved Health Outcomes | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $679,104 | September 1, 2022 | July 31, 2027 | PERNELL, BRANDI | reporter.nih.gov |
| Therapeutic Targets in Acute Chest Syndrome | NIH | National Heart, Lung, and Blood Institute | 2025 | $678,698 | February 7, 2022 | January 31, 2027 | OFORI-ACQUAH, SOLOMON FIIFI | reporter.nih.gov |
| Sickle Cell Anemia, Splenic Pathology, and Hydroxyurea in Sub-Saharan Africa | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $678,240 | July 21, 2020 | June 30, 2025 | SMART, LUKE | reporter.nih.gov |
| An mHealth Strategy to Improve Medication Adherence in Adolescents with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $673,920 | March 1, 2020 | February 28, 2026 | BADAWY, SHERIF MOHAMED | reporter.nih.gov |
| Red blood cell modifiers for Plasmodium falciparum growth in sickle cell disease erythrocytes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $671,760 | August 1, 2020 | April 30, 2025 | ARCHER, NATASHA MARIE BERNADETTE | reporter.nih.gov |
| Immunological mechanisms underlying acupuncture analgesia in patients with sickle cell disease | NIH | National Center for Complementary & Integrative Health | 2025 | $665,312 | August 20, 2025 | May 31, 2030 | WANG, YING | reporter.nih.gov |
| Examination of Initiating Factors that Regulate Red Blood Cell Alloimmunization | NIH | National Heart, Lung, and Blood Institute | 2025 | $664,240 | May 1, 2017 | April 30, 2029 | STOWELL, SEAN R | reporter.nih.gov |
| Microfluidic Impedance Red Cell Assay (MIRCA) for Emerging Pharmacologic and Gene based Therapies for Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2022 | $663,187 | September 12, 2022 | August 31, 2024 | GURKAN, UMUT A. | reporter.nih.gov |
| NET stabilization: mechanistic and therapeutic studies in thromboinflammatory disoders | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $655,999 | March 5, 2021 | February 28, 2025 | GOLLOMP, KANDACE | reporter.nih.gov |
| Improving SCD Care using Web-based Guidelines, Nurse Care Managers and Peer Mentors in Primary Care and Emergency Departments in Central North Carolina | NIH | National Heart, Lung, and Blood Institute | 2021 | $654,479 | August 5, 2016 | June 30, 2023 | TANABE, PAULA | reporter.nih.gov |
| Characterization of B Lymphocyte Deficiency in Pediatric Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $652,688 | June 20, 2020 | May 31, 2025 | TUBMAN, VENEE N | reporter.nih.gov |
| Donor Red Blood Cell Survival in Recipients with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $646,383 | September 15, 2025 | June 30, 2030 | YEE, MARIANNE ELAINE MCPHERSON | reporter.nih.gov |
| Implementation of a Sickle Cell Enhanced Novel Care Network in South Carolina (iSCENSC) | NIH | National Heart, Lung, and Blood Institute | 2021 | $646,201 | August 5, 2016 | June 30, 2024 | FLOREZ, HERMES JOSE | reporter.nih.gov |
| RE-aiming at Hydroxyurea Adherence for Sickle cell with mHealth (RE-HASH) | NIH | National Heart, Lung, and Blood Institute | 2021 | $638,420 | August 8, 2016 | June 30, 2023 | HANKINS, JANE SILVA | reporter.nih.gov |
| Cilia as a biomarker of CNS vascular health | NIH | National Heart, Lung, and Blood Institute | 2021 | $628,041 | September 3, 2020 | August 31, 2022 | RAMCHANDRAN, RAMANI | reporter.nih.gov |
| MicroRNA-based epigenetic approach to induce fetal hemoglobin | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $610,015 | July 13, 2020 | June 30, 2024 | STARLARD-DAVENPORT, ATHENA | reporter.nih.gov |
| MULTIsite feasibility of MUSIc therapy to address Quality Of Life in Sickle cell disease (MULTI-MUSIQOLS) | NIH | National Center for Complementary & Integrative Health | 2023 | $609,643 | September 18, 2023 | August 31, 2024 | DUSEK, JEFFERY A | reporter.nih.gov |
| Discovery and validation of single cell biomarkers for clinical outcome in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $608,126 | December 15, 2024 | November 30, 2028 | WOOD, DAVID KEVIN | reporter.nih.gov |
| Diverse effects of hemin on the endothelium contribute to pulmonary complications of sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2024 | $607,535 | September 17, 2024 | August 31, 2025 | FRAIDENBURG, DUSTIN | reporter.nih.gov |
| Sickle Cell Trait Mice are More Susceptible to Chlorine Exposure and Haptoglobin Improves the Outcomes | NIH | National Institute of Environmental Health Sciences | 2022 to 2024 | $594,000 | April 1, 2022 | March 31, 2025 | ALISHLASH, AMMAR | reporter.nih.gov |
| Clinical and Molecular based prognostic factors for Venous Thromboembolism (VTE) in Children with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $586,792 | August 15, 2023 | July 31, 2028 | BETENSKY, MARISOL | reporter.nih.gov |
| Endothelin 1 in iron handling in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $573,821 | May 1, 2025 | January 31, 2030 | KASZTAN, MALGORZATA | reporter.nih.gov |
| Targeted Identification of Dual Acting Antisickling Agents for Sickle Cell Disease Therapy | NIH | National Heart, Lung, and Blood Institute | 2023 | $572,290 | March 20, 2021 | February 28, 2025 | SAFO, MARTIN K | reporter.nih.gov |
| Cerebrovascular reserve and white matter disease in patients with anemia | NIH | National Heart, Lung, and Blood Institute | 2021 | $562,181 | January 15, 2018 | December 31, 2022 | WOOD, JOHN C | reporter.nih.gov |
| SC-Links - Linking the Sickle Cell Community, Providers and Systems to Improve Sickle Cell Disease Care | NIH | National Heart, Lung, and Blood Institute | 2021 | $559,570 | August 5, 2016 | June 30, 2024 | VICHINSKY, ELLIOTT P | reporter.nih.gov |
| Small Molecule Therapeutics for Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2023 | $547,199 | February 15, 2023 | January 31, 2025 | ARCHER, DAVID R | reporter.nih.gov |
| Development of selective calpain-1 inhibitors for chronic pain | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $546,376 | July 1, 2021 | December 31, 2023 | NWANKWO, JENNIFER O | reporter.nih.gov |
| Nanochelation Therapies for Iron Overload Disorders | NIH | National Heart, Lung, and Blood Institute | 2021 | $543,043 | January 1, 2021 | August 31, 2023 | KIM, JONGHAN | reporter.nih.gov |
| Elevating Mentoring Possibilities for Overcoming Withstanding Educational Roadblocks in Sickle Cell Disease (EMPOWER SCD): STEMM mentoring for youth with sickle cell disease | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $541,452 | September 1, 2024 | August 31, 2029 | GEE, BEATRICE E | reporter.nih.gov |
| Effective Network to advance Scientific Evidence related to Mechanisms of music-Based interventions (ENSEMBLE) | NIH | National Center for Complementary & Integrative Health | 2023 | $526,172 | September 21, 2023 | December 31, 2023 | DUSEK, JEFFERY A | reporter.nih.gov |
| Metabolic adaption of macrophages to heme detoxification in systemic vascular inflammation | NIH | National Heart, Lung, and Blood Institute | 2022 | $517,372 | September 22, 2022 | August 31, 2024 | LEITINGER, NORBERT | reporter.nih.gov |
| Integrating Nurse Champion Model for Group Reproductive Genetic Counseling forSickle Cell Hemoglobinopathies into Primary Care: A Pilot Implementation ScienceStudy | NIH | National Human Genome Research Institute | 2021 to 2023 | $516,327 | March 15, 2022 | June 30, 2025 | JAJA, CHEEDY | reporter.nih.gov |
| Novel Pathways in Ischemic Stroke in Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2021 | $515,958 | August 1, 2019 | June 30, 2024 | FLANAGAN, JONATHAN MICHAEL | reporter.nih.gov |
| Mechanisms of platelet stimulation in hemolysis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $513,184 | February 15, 2022 | January 31, 2027 | NOLFI-DONEGAN, DEIRDRE | reporter.nih.gov |
| Fundamentals of Anti-Sickling Therapies | NIH | National Heart, Lung, and Blood Institute | 2025 | $503,870 | September 1, 2025 | June 30, 2029 | FERRONE, FRANK A | reporter.nih.gov |
| Oxidative Cysteine Modification by Thiol Isomerases in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $498,000 | August 1, 2024 | July 31, 2027 | YANG, MOUA | reporter.nih.gov |
| MicroRNA as a target for fetal hemoglobin inducing agents in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $497,996 | February 1, 2021 | January 31, 2023 | HE, YING | reporter.nih.gov |
| Invasive Pneumococcal Disease and Carriage among Children with Sickle Cell Disease in Ghana: A Post-vaccination Study | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $489,262 | May 12, 2022 | April 30, 2027 | SAMPANE-DONKOR, ERIC | reporter.nih.gov |
| R15: Enhancement of Genome Editing in Hematopoietic Stem Cells by Nucleic Acids Nanoparticles Delivery of CRISPR/CAS System | NIH | National Heart, Lung, and Blood Institute | 2025 | $486,291 | February 1, 2025 | January 31, 2028 | FU, JINGLIN | reporter.nih.gov |
| BMT Core: Southeast Bone Marrow Transplant Consortium | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $485,186 | August 15, 2024 | June 30, 2031 | WALLER, EDMUND K | reporter.nih.gov |
| School Readiness Intervention for Preschool Children with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $484,248 | May 10, 2023 | April 30, 2028 | HEITZER, ANDREW M | reporter.nih.gov |
| Development of platform technology to measure kinetics and equilibrium concentration of sickle hemoglobin polymerization in single RBCs for drug potency assessment and patient risk stratification | NIH | National Heart, Lung, and Blood Institute | 2025 | $483,852 | March 18, 2025 | February 28, 2027 | HIGGINS, JOHN MATTHEW | reporter.nih.gov |
| Core Clinical Consortium for Blood and Marrow Transplant Clinical Trials Network | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $476,654 | September 30, 2001 | June 30, 2024 | HSU, JACK W | reporter.nih.gov |
| Sickle Pan Africa Research Consortium TRAINing (SPARC- TRAIN) Program | NIH | Fogarty International Center | 2024 to 2025 | $467,365 | April 1, 2024 | February 28, 2029 | NNODU, OBIAGELI EUNICE | reporter.nih.gov |
| Inflammation-associated Autophagy Dysfunction | NIH | National Heart, Lung, and Blood Institute | 2025 | $465,000 | April 1, 2025 | May 31, 2028 | DAVIZON-CASTILLO, PAVEL | reporter.nih.gov |
| The microbiome determines organ damage development in sickle cell disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $461,538 | September 15, 2022 | September 14, 2027 | LI, HUIHUI | reporter.nih.gov |
| Pathogenic Role of IL-18 in Sickle Cell Cardiomyopathy and Inducible Ventricular Tachycardia | NIH | National Heart, Lung, and Blood Institute | 2021 | $461,445 | April 1, 2017 | March 31, 2022 | DESAI, ANKIT A | reporter.nih.gov |
| SMILE: Sickle Cell Disease Microbiologic and Immunologic Links to Health Equity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $459,079 | February 1, 2023 | January 31, 2026 | KOPP, BENJAMIN T | reporter.nih.gov |
| Longitudinal study of cognitive remediation to prepare for transition of care in youth with sickle cell disease | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $458,496 | July 7, 2022 | March 31, 2027 | MURDAUGH, DONNA | reporter.nih.gov |
| Erythrocyte Autophagy Proteins as Potential Non-opioid Novel Targets for Pain in Sickle Cell Disease | NIH | National Center for Complementary & Integrative Health | 2022 | $455,195 | September 22, 2022 | August 31, 2024 | RAMASAMY, JAGADEESH | reporter.nih.gov |
| Zinc Supplementation in SCD: A Precursor to the Think Zinc for Bones Trial | NIH | National Heart, Lung, and Blood Institute | 2025 | $449,538 | August 15, 2025 | July 31, 2027 | FUNG, ELLEN B | reporter.nih.gov |
| Characterizing subphenotypes of long COIVD in patients with sickle cell disease | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $445,920 | May 30, 2024 | December 31, 2026 | SHARATHKUMAR, ANJALI ALATKAR | reporter.nih.gov |
| The Pro-Inflammatory Effects of Acute Exercise in Children with Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2021 | $445,812 | April 1, 2017 | March 31, 2024 | LIEM, ROBERT IE | reporter.nih.gov |
| Interaction of sickle cell trait with human apolipoprotein E ε4: Impact on brain structure, brain lipidomics, neuroinflammation and cognitive deficit | NIH | National Institute on Aging | 2024 | $445,500 | September 1, 2024 | August 31, 2026 | HYACINTH, HYACINTH IDU | reporter.nih.gov |
| Patrolling Monocytes in Sickle Pain Crisis and following Transfusion | NIH | National Heart, Lung, and Blood Institute | 2021 | $445,000 | July 15, 2019 | February 28, 2022 | YAZDANBAKHSH, KARINA | reporter.nih.gov |
| NET stabilization: mechanistic and therapeutic studies studying the role of NETs in thromboinflammatory disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $445,000 | March 17, 2025 | February 29, 2028 | GOLLOMP, KANDACE | reporter.nih.gov |
| Modulation of Neutrophil Function by Red Cell Exchange in SCD Patients | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $444,125 | July 24, 2025 | June 30, 2027 | LEE, GRACE MING | reporter.nih.gov |
| Defining the mechanisms of hemoglobin switching and genotoxicities associated with its manipulation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $443,456 | April 1, 2022 | August 19, 2024 | DOERFLER, PHILLIP A | reporter.nih.gov |
| Bone Marrow Niche dysfunction in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $443,011 | February 4, 2021 | April 30, 2022 | CARLESSO, NADIA | reporter.nih.gov |
| Identifying novel clinical, genetic and proteomic risk factors for sickle cell nephropathy. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $442,750 | April 15, 2021 | March 31, 2023 | ASHLEY-KOCH, ALLISON E | reporter.nih.gov |
| Epigenetic Age Acceleration and Psychoneurological Symptoms in Sickle Cell Disease | NIH | National Institute of Nursing Research | 2022 to 2023 | $442,750 | March 18, 2022 | February 29, 2024 | KNISELY, MITCHELL ROBERT | reporter.nih.gov |
| NOVEL INNATE MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN ALLOGENEIC HCT FOR HEMOGLOBINOPATHIES | NIH | National Heart, Lung, and Blood Institute | 2021 | $441,168 | January 1, 2018 | December 31, 2022 | PILLAI, ASHA BHASKARAN | reporter.nih.gov |
| Exploring the Mediterranean Diet as A Promising Approach for Alleviating Chronic Pain in Sickle Cell Disease | NIH | National Center for Complementary & Integrative Health | 2025 | $437,458 | April 21, 2025 | March 31, 2027 | TUSSING-HUMPHREYS, LISA | reporter.nih.gov |
| 'Omics predictors of Sickle Cell Severity and Survival | NIH | National Institute on Aging | 2024 | $430,956 | August 1, 2024 | July 31, 2026 | ASHLEY-KOCH, ALLISON E | reporter.nih.gov |
| Home-Based Self-Management of Chronic Pain in Adults with Sickle Cell Disease: Applying a Biopsychosocial and Technological Approach | NIH | National Institute of Nursing Research | 2021 to 2022 | $430,000 | March 19, 2021 | February 29, 2024 | MATTHIE, NADINE | reporter.nih.gov |
| Neurovascular frataxin and cognitive dysfunction in sickle cell disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $429,580 | September 25, 2023 | August 31, 2025 | HAZRA, RIMI | reporter.nih.gov |
| Acoustically-driven optical-interferometric microscope for cell characterization | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $424,050 | January 1, 2021 | December 31, 2022 | ANTHONY, BRIAN W | reporter.nih.gov |
| Deep-UV Microscopy for Real-Time Adequacy Analysis of Bone Marrow Aspirates | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2024 | $423,145 | August 1, 2023 | December 31, 2024 | ROBLES, FRANCISCO E | reporter.nih.gov |
| Precise in vivo gene editing of HSPC for the treatment of genetic hematologic diseases | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $420,750 | January 1, 2023 | December 31, 2025 | TONG, SHENG | reporter.nih.gov |
| Predicting Pediatric Sickle Cell Disease Acute Pain Using Mathematical Models Based on mHealth Data | NIH | National Institute of Dental & Craniofacial Research | 2022 | $420,357 | September 20, 2022 | September 19, 2025 | VALRIE, CECELIA R | reporter.nih.gov |
| In vivo gene editing of hematopoietic stem and progenitor cells | NIH | National Heart, Lung, and Blood Institute | 2021 | $417,500 | March 1, 2018 | February 29, 2024 | WAGERS, AMY JO | reporter.nih.gov |
| Trajectory of Cognitive Functioning in Youth with Sickle Cell Disease without Cerebral Infarction | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $411,530 | March 1, 2019 | September 30, 2024 | HARDY, STEVEN JAMES | reporter.nih.gov |
| Precision Apheresis: stem cell isolation from patients with sickle cell disease for gene therapy using high-throughput microfluidics | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $410,469 | August 5, 2023 | July 31, 2028 | MISHRA, AVANISH | reporter.nih.gov |
| Decoding lineage-specific gene regulation across hematopoiesis | NIH | Office of the Director, National Institutes of Health | 2025 | $406,250 | August 11, 2025 | July 31, 2030 | TRAXLER, ELIZABETH | reporter.nih.gov |
| 1/2 A comparison of individualized vs. weight based protocols to treat vaso-occlusive episodes in Sickle Cell Disease (COMPARE VOE) | NIH | National Heart, Lung, and Blood Institute | 2021 | $406,201 | September 7, 2018 | August 31, 2024 | TANABE, PAULA | reporter.nih.gov |
| Early Identification Of Developmental Delay Among Infants And Toddlers With Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $405,482 | July 1, 2023 | June 30, 2028 | HOYT, CATHERINE ROSE | reporter.nih.gov |
| Heme-Based Immune Dysregulation in Critical Illness | NIH | National Institute of General Medical Sciences | 2025 | $402,500 | August 1, 2025 | July 31, 2030 | REMY, KENNETH EUGENE | reporter.nih.gov |
| Contributions of biopsychosocial factors in sickle cell disease pain | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $402,258 | July 15, 2020 | June 30, 2024 | ROACH, KEESHA L. | reporter.nih.gov |
| Development of stretchable optical sensors for measurement of penile hemodynamics | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 | $399,613 | September 7, 2024 | September 6, 2026 | LAFAVOR, JUSTIN DAVID | reporter.nih.gov |
| Next generation of delivery platform for Prime editors based on an RNA vector for Sickle cell disease: the “all-in-one” vector | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $399,465 | June 1, 2024 | December 31, 2026 | DEVAUX, PATRICIA | reporter.nih.gov |
| Sickle Cell Disease Functional Assessment Validation and Exercise Pilot Intervention | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $396,814 | July 20, 2023 | June 30, 2025 | OYEDEJI, CHARITY IBILOLA | reporter.nih.gov |
| Homologous Recombination Mediated Gene Correction for the Hemoglobinopathies | NIH | National Heart, Lung, and Blood Institute | 2021 | $395,344 | August 1, 2018 | June 30, 2022 | PORTEUS, MATTHEW H | reporter.nih.gov |
| Transcranial Doppler Ultrasonography Clinical and Research Centers of Excellence in Sub-Saharan Africa | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $393,121 | August 1, 2021 | July 31, 2024 | OBRIEN, NICOLE | reporter.nih.gov |
| Developing a low cost, highly compact holographic imaging based microfluidic cell sorting system using 3D printing | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 | $389,751 | September 1, 2023 | August 31, 2025 | HONG, JIARONG | reporter.nih.gov |
| Mechanisms of coagulation-dependent pathologies in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $388,750 | August 15, 2018 | May 31, 2023 | PAWLINSKI, RAFAL L | reporter.nih.gov |
| Formative Implementation Research on Translating Evidence to Hospital Care for People Living With Sickle Cell Disease (FIRES) | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $382,326 | September 17, 2024 | August 31, 2029 | JENKINS, ASHLEY | reporter.nih.gov |
| Developmental Pharmacology of Hydroxyurea Across the Age Span for the Treatment of Sickle Cell Anemia | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2023 | $370,016 | February 1, 2022 | January 31, 2025 | MCGANN, PATRICK THOMAS | reporter.nih.gov |
| Molecular mechanism of Sickle Cell Hepatic Crisis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $365,867 | July 15, 2020 | August 31, 2023 | PRADHAN-SUNDD, TIRTHADIPA | reporter.nih.gov |
| Using Patient-Centered Guidelines in a Technology Platform to Improve Health Care in Adults with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $364,539 | June 1, 2018 | May 31, 2025 | CRONIN, ROBERT M | reporter.nih.gov |
| Children's National Stimulating Access to Research in Residency (CNStARR) Program (NHLBI) | NIH | National Heart, Lung, and Blood Institute | 2021 | $363,899 | July 1, 2018 | June 30, 2023 | TEACH, STEPHEN JOHN | reporter.nih.gov |
| An implementation toolkit for the use of hydroxyurea in the treatment of sickle cell aneamia in Ugandan children | NIH | Fogarty International Center | 2021 to 2022 | $360,840 | June 7, 2021 | May 31, 2024 | OPOKA, ROBERT | reporter.nih.gov |
| The Effects of Older Red Cell Units in Adults with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $356,400 | April 1, 2021 | March 31, 2024 | KARAFIN, MATTHEW S | reporter.nih.gov |
| A Rapid and Inexpensive Point-of-Care Test for Beta-Thalassemia Carriers | NIH | National Heart, Lung, and Blood Institute | 2021 | $345,189 | August 15, 2020 | July 31, 2022 | GEISBERG, MARK | reporter.nih.gov |
| Reducing Morbidity in Sickle Cell Disease-Prevent Acute Chest Syndrome system (PACSystem) pilot study | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $343,943 | June 1, 2024 | May 31, 2029 | MORRONE, KERRY | reporter.nih.gov |
| Designing an Implementation Strategy for Delivering Routine Mental Health Screening and Treatment for Adolescents and Adults with Sickle Cell Disease | NIH | National Institute of Mental Health | 2021 | $343,259 | September 15, 2020 | August 31, 2023 | JONASSAINT, CHARLES RICHARD | reporter.nih.gov |
| A Double Blinded Randomized Feasibility Trial on the Use of Plant Based Omega-3-Fatty Acids (Flaxseed) to Improve Inflammation Driven Pain Outcomes in Children with Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $342,360 | April 1, 2024 | March 31, 2029 | DIKE, CHINENYE REBECCA | reporter.nih.gov |
| The Nurse Champion Model for Sickle Cell Disease Early Diagnosis and Care Access | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2023 | $341,092 | April 15, 2021 | October 31, 2025 | JAJA, CHEEDY | reporter.nih.gov |
| Primary Prevention of Stroke in Children with Sickle Cell Anaemia in Nigeria: Community vs Teaching Hospital | NIH | Fogarty International Center | 2021 to 2024 | $340,200 | August 1, 2020 | July 31, 2025 | BELLO-MANGA, HALIMA | reporter.nih.gov |
| Optimizing hematopoietic stem cell transplantation to treat non-malignant disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $338,312 | September 17, 2024 | June 30, 2029 | PERSAUD, STEPHEN PHILLIP | reporter.nih.gov |
| Pilot-testing and Implementation of an Integrated Sickle-cell Screening and Violence Prevention Program in Antenatal Care Settings in India (PIVOT) | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $333,893 | August 1, 2024 | July 31, 2029 | HALIM, NAFISA | reporter.nih.gov |
| Studying Intra-Individual Pain Variability in Sickle Cell Disease and Resolution of Pain after Hematopoietic Cell Transplant: A Novel Model System to Elucidate Mechanisms of Transition to Chronic Pain | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $333,091 | August 15, 2018 | August 31, 2023 | BAKSHI, NITYA | reporter.nih.gov |
| Long-term health-related quality of life and cost of allogeneic hematopoietic cell transplantation for children with sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $332,681 | August 1, 2018 | July 31, 2024 | ARNOLD, STACI D. | reporter.nih.gov |
| (SCANS) Sickle Cell Anemia Neurodevelopmental Screening - Mentoring and Research in Patient Oriented Research | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $332,622 | September 20, 2019 | July 31, 2025 | KING, ALLISON A | reporter.nih.gov |
| Combination treatment with Vepoloxamer and tPA for acute stroke | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $329,219 | June 1, 2017 | April 30, 2023 | ZHANG, LI | reporter.nih.gov |
| Oxidative Cysteine Modification by Thiol Isomerases in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $328,968 | August 30, 2022 | June 30, 2024 | YANG, MOUA | reporter.nih.gov |
| Minocycline as a potential therapy for neuroinflammation and cognitive deficit in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $327,919 | December 15, 2020 | January 31, 2021 | HYACINTH, HYACINTH IDU | reporter.nih.gov |
| Mentoring in Patient-Oriented Research focused on Neurological Complications of Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $325,632 | August 15, 2019 | July 31, 2025 | JORDAN, LORI CHAFFIN | reporter.nih.gov |
| Iron Catalyzed H2S and its Prevalence in Hemolytic and Iron Overload Disorders | NIH | National Heart, Lung, and Blood Institute | 2021 | $322,000 | July 1, 2019 | June 30, 2024 | HINE, CHRISTOPHER MICHAEL | reporter.nih.gov |
| Characterizing Frailty in Older Adults with Sickle Cell Disease Using a Sickle Cell Frailty Index (FI-SCD) | NIH | National Institute on Aging | 2021 to 2022 | $322,000 | August 15, 2021 | November 30, 2023 | OYEDEJI, CHARITY IBILOLA | reporter.nih.gov |
| Roles of Red Blood Cell Derived Extracellular Vesicles in Complement Activation and Thromboinflammation in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $319,458 | April 19, 2023 | July 31, 2027 | AN, RAN | reporter.nih.gov |
| Adaptation and Pilot Testing of a Patient-provider Communication Intervention for Adults with Sickle Cell Disease | NIH | National Institute of Nursing Research | 2024 to 2025 | $318,904 | August 28, 2024 | January 31, 2027 | O'BRIEN, JULIA ANN | reporter.nih.gov |
| Manufacturing and Analytical Validation of the Microfluidic Impedance Red Cell Assay (MIRCA) for Commercial Viability | NIH | National Heart, Lung, and Blood Institute | 2025 | $316,800 | September 15, 2025 | March 31, 2026 | FEDERICI, CHIARA | reporter.nih.gov |
| Development and Evaluation of an Information Management and Communication System for Population-wide Point-of-Care Infant Sickle Cell Disease Screening. | NIH | Fogarty International Center | 2021 to 2022 | $313,006 | August 16, 2021 | August 10, 2023 | SEWANKAMBO, NELSON K | reporter.nih.gov |
| The role of HbF decline and its determinants on Sickle Cell Disease expression in the first three years of life. | NIH | Fogarty International Center | 2021 to 2023 | $312,499 | August 1, 2019 | April 30, 2024 | NKYA, SIANA WATOKY | reporter.nih.gov |
| Protein arginine methyltransferase-mediated vascular dementia in sickle cell disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $304,048 | April 15, 2023 | December 31, 2023 | LIN, HUNG WEN (KEVIN) | reporter.nih.gov |
| Identifying Mechanisms Involved in Hydroxyurea-Mediated Reduction in Vaso-occlusive Adhesive Events in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $303,192 | September 5, 2023 | August 31, 2025 | WHITE, JENNELL | reporter.nih.gov |
| In vivo Sickle Cell Disease Gene Therapy Using a Novel Virus Like Particle | NIH | National Heart, Lung, and Blood Institute | 2024 | $300,000 | September 10, 2024 | September 9, 2025 | JOHNSON, DAVID SCOTT | reporter.nih.gov |
| MULTIsite feasibility of MUSIc therapy to address Quality Of Life in Sickle cell disease (MULTI-MUSIQOLS) | NIH | National Center for Complementary & Integrative Health | 2024 | $300,000 | September 18, 2023 | August 31, 2026 | DUSEK, JEFFERY A | reporter.nih.gov |
| Allosteric Modulation of PAR1 for the Treatment of Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2023 | $299,790 | September 1, 2023 | February 28, 2025 | DOCKENDORFF, CHRISTOPHER | reporter.nih.gov |
| RHODA: Rapid Hemoglobin-Oxygen Dissociation Assay | NIH | National Heart, Lung, and Blood Institute | 2024 | $295,920 | January 1, 2024 | December 31, 2025 | GALEN, PETER | reporter.nih.gov |
| Pharmacologic Inhibition of NLRP3 Inflammasome-Dependent Injury following Vaso-occlusion in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $295,247 | September 1, 2021 | August 31, 2024 | LIGHT, DAVID RICHARD | reporter.nih.gov |
| Methylphenidate to Address Executive Functioning Impairment in Pediatric Patients with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $277,500 | August 1, 2025 | July 31, 2027 | HEITZER, ANDREW M | reporter.nih.gov |
| Critical role of NRF2 in globin gene regulation in sickle cell disease mouse models | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $277,200 | September 17, 2019 | June 30, 2024 | ZHU, XINGGUO | reporter.nih.gov |
| A Pilot Study of an Enhanced Program to Promote Adherence to eHealth Cognitive Rehabilitation in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $273,000 | March 1, 2024 | February 28, 2027 | HARDY, STEVEN JAMES | reporter.nih.gov |
| Predictors of Pain Severity and Pain-Related Outcomes in Individuals with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $270,918 | August 15, 2023 | July 31, 2025 | KENNEY, MARTHA OBENG | reporter.nih.gov |
| SCH: INT: Collaborative Research: Development and analysis of new mathematical and statistical models for chronic pain | NIH | National Center for Complementary & Integrative Health | 2021 | $270,467 | September 13, 2018 | August 31, 2024 | ABRAMS, DANIEL M | reporter.nih.gov |
| Development of POC system for patient condition and treatment monitoring in Sickle Cell Disease through hypoxia-induced sickling | NIH | National Heart, Lung, and Blood Institute | 2024 | $265,347 | September 20, 2024 | March 19, 2026 | HINES, PATRICK | reporter.nih.gov |
| Using Multi-Spectral Imaging with Microchip Electrophoresis to Accurately Screen Newborns for Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $256,580 | April 1, 2021 | March 31, 2022 | GALEN, PETER | reporter.nih.gov |
| Evaluating accessory cells to improve homing and engraftment efficiency of CD34+ cells from sickle cell disease patients | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $256,200 | September 1, 2024 | July 31, 2026 | LIU, YUNFENG | reporter.nih.gov |
| Multidisciplinary sickle cell disease obstetrics care program in Ghana: Non-academic vs.Academic Hospital (Pilot Study) | NIH | Fogarty International Center | 2023 to 2025 | $255,940 | August 11, 2023 | April 30, 2028 | ASARE, EUGENIA VICKY | reporter.nih.gov |
| Collaborative Care to Improve Resilience and Quality of Life among Youth with Non-malignant Blood Disorders | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $252,946 | September 1, 2024 | August 31, 2029 | ROSENBERG, ABBY R | reporter.nih.gov |
| DNA damage responses to genome editing in hematopoietic stem cells | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $242,048 | September 8, 2025 | August 31, 2027 | DOERFLER, PHILLIP A | reporter.nih.gov |
| Nutrition-based interventions to ameliorate pain in sickle cell disease | NIH | National Center for Complementary & Integrative Health | 2024 to 2025 | $241,268 | April 1, 2024 | March 31, 2026 | ARGUETA, DONOVAN ALEXANDER | reporter.nih.gov |
| Evaluation of ovarian reserve, aging and fertility preservation in women with sickle cell disease | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $236,550 | February 1, 2021 | June 30, 2024 | YU, BO | reporter.nih.gov |
| Hormonal contraception choice and safety among people with sickle cell disease | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 | $234,750 | September 5, 2024 | August 31, 2025 | HOWARDS, PENELOPE P. | reporter.nih.gov |
| Reproductive Health of Young Adult Women Who Have Sickle Cell Disease | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $234,000 | July 15, 2020 | June 30, 2023 | HOWARDS, PENELOPE P. | reporter.nih.gov |
| Sickle cell disease gut dysbiosis effects on CNS pain processing | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $230,256 | August 1, 2021 | January 31, 2023 | SADLER, KATELYN | reporter.nih.gov |
| Mechanisms underlying increased risk of hematological malignancy in sickle cell disease. | NIH | National Cancer Institute | 2025 | $225,101 | April 1, 2025 | March 31, 2027 | MALIK, PUNAM | reporter.nih.gov |
| Molecular Mechanism of Sickle Cell Hepatic Crisis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $221,969 | July 15, 2020 | April 30, 2026 | PRADHAN-SUNDD, TIRTHADIPA | reporter.nih.gov |
| Mechanisms and consequences of sickle cell disease-induced cycling in hematopoietic stem cells | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $218,266 | April 1, 2022 | March 31, 2025 | BARVE, ADITYA SHIRISH | reporter.nih.gov |
| Indoor environmental exposures and pulmonary inflammation and morbidity in sickle cell anemia | NIH | National Heart, Lung, and Blood Institute | 2021 | $199,535 | June 1, 2018 | May 31, 2023 | SADREAMELI, SARA CHRISTINA | reporter.nih.gov |
| Defining the Mechanism of Complement Pathway Activation during Pregnancy and its Role in Adverse Pregnancy Outcomes in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $197,259 | August 1, 2025 | July 31, 2030 | GERBER, GLORIA FRANCES | reporter.nih.gov |
| Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $196,753 | September 5, 2017 | June 30, 2023 | WILLIAMS, DAVID A | reporter.nih.gov |
| The Role of Blood-Brain Barrier Disruption on Ischemic Brain Injury and Cognitive Impairment in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $195,846 | August 1, 2025 | April 30, 2030 | WANG, YAN | reporter.nih.gov |
| Dronabinol for the reduction of chronic pain and inflammation in people with sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $194,184 | September 1, 2021 | May 31, 2022 | CURTIS, SUSANNA | reporter.nih.gov |
| HbS oligomers as a therapeutic target in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $187,064 | April 16, 2020 | March 31, 2022 | WOOD, DAVID KEVIN | reporter.nih.gov |
| Model-Informed Evaluation of Hydroxyurea Exposure in Special Populations | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2023 | $179,047 | June 24, 2022 | January 5, 2024 | DONG, MIN | reporter.nih.gov |
| Age-Dependence of Cerebral Oxygen Metabolism and Stroke Risk in Pediatric Sickle Cell Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $176,279 | January 1, 2017 | December 31, 2021 | GUILLIAMS, KRISTIN | reporter.nih.gov |
| The Nurse Champion Model for Sickle Cell Disease Early Diagnosis and Care Access | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $176,144 | April 15, 2021 | January 31, 2022 | JAJA, CHEEDY | reporter.nih.gov |
| Investigating Platelet Immune Mechanisms in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $168,048 | September 15, 2025 | June 30, 2030 | GU, SEAN XIANG | reporter.nih.gov |
| Nonpharmacological Treatment Effects on Proinflammatory Biomarkers among Youth with Chronic Sickle Cell Pain | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $165,625 | September 1, 2022 | August 31, 2025 | SIL, SOUMITRI | reporter.nih.gov |
| Neuroimaging, Neurocognitive, and Plasma Protein Markers of Brain Injury in Young Children with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $162,000 | September 1, 2021 | August 31, 2024 | LANCE, EBONI I | reporter.nih.gov |
| Self-Assembling Peptide Nanoparticles for in vivo Genome Editor Delivery to Hematopoietic Stem Cells | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $161,206 | June 1, 2023 | May 31, 2027 | EWEJE, FEYISAYO RONALD | reporter.nih.gov |
| Defining the mechanisms of hemoglobin switching and genotoxicities associated with its manipulation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $158,220 | September 21, 2024 | December 31, 2026 | DOERFLER, PHILLIP A | reporter.nih.gov |
| RASA3 is a Candidate Gene in the Pathogenesis of Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $156,416 | August 22, 2025 | July 31, 2030 | PROHASKA, CLARE | reporter.nih.gov |
| Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $156,340 | June 15, 2025 | May 31, 2030 | MULCHAN, SIDDIKA | reporter.nih.gov |
| The microbiome determines organ damage development in sickle cell disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 | $156,027 | September 15, 2022 | April 14, 2023 | LI, HUIHUI | reporter.nih.gov |
| Dissecting the spectrum of genetic architectures underlying congenital heart defects. | NIH | National Heart, Lung, and Blood Institute | 2021 | $156,000 | January 1, 2020 | December 31, 2022 | ARBOLEDA, VALERIE A | reporter.nih.gov |
| Super-resolution mobile microscopy | NIH | National Institute of Biomedical Imaging and Bioengineering | 2025 | $153,000 | August 1, 2025 | July 31, 2027 | LU, JIAN-YU | reporter.nih.gov |
| Investigating the Role of Heme in Acute and Chronic Sickle Cell Disease Pain | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $152,476 | August 1, 2023 | July 31, 2027 | ZORN, SAMUEL JOSHUA | reporter.nih.gov |
| MRI-based Quantitative Brain Oximetry for Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $151,843 | January 1, 2019 | December 5, 2021 | LI, WENBO | reporter.nih.gov |
| Sickle cell disease severity prediction from the magnetic signature and hemoglobin content of blood cells | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $150,220 | August 1, 2025 | July 31, 2027 | GOMEZ PASTORA, JENIFER | reporter.nih.gov |
| Evidence-based Approaches to Chronic Pain Management in Youth with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $148,778 | August 1, 2017 | September 30, 2022 | SIL, SOUMITRI | reporter.nih.gov |
| Using machine learning to understand cardiopulmonary and renal end organ complications for individuals with SCD | NIH | National Heart, Lung, and Blood Institute | 2025 | $146,013 | September 1, 2025 | June 30, 2029 | SINGH, ASHIMA | reporter.nih.gov |
| SMYLS: A Self-Management Program for Youth Living with Sickle Cell Disease | NIH | National Institute of Nursing Research | 2021 | $142,030 | April 18, 2019 | March 31, 2022 | PHILLIPS, SHANNON M. | reporter.nih.gov |
| Mechanisms of Hydroxyurea Efficacy in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $140,540 | August 1, 2017 | June 30, 2022 | WALKER, AISHA LANETTE | reporter.nih.gov |
| Mentoring & Patient-Oriented Research in Sickle Cell-Related Kidney Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $137,219 | December 24, 2024 | November 30, 2029 | SARAF, SANTOSH | reporter.nih.gov |
| Molecular determinants of fetal hemoglobin induction by hydroxyurea to treat sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $133,286 | January 16, 2021 | August 31, 2023 | DO, BRIAN TSHAO | reporter.nih.gov |
| Chronic dehydration in sickle cell disease: An actionable biomarker to prevent vaso-occlusive episodes? | NIH | National Heart, Lung, and Blood Institute | 2024 | $131,938 | April 15, 2024 | March 31, 2026 | KARAFIN, MATTHEW S | reporter.nih.gov |
| Chronic dehydration in sickle cell disease: An actionable biomarker to prevent vaso-occlusive episodes | NIH | National Heart, Lung, and Blood Institute | 2025 | $131,050 | April 1, 2025 | March 31, 2027 | CAUGHEY, MELISSA C | reporter.nih.gov |
| Probing silent cerebral infarct pathogenesis in sickle cell disease with cerebrovascular MRI | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $129,284 | September 1, 2022 | August 31, 2025 | ZVOLANEK, KRISTINA | reporter.nih.gov |
| Patient-Oriented Research Mentoring for the Investigation of Acute and Chronic Sickle Cell Disease Pain | NIH | National Heart, Lung, and Blood Institute | 2025 | $122,840 | August 1, 2025 | July 31, 2030 | BRANDOW, AMANDA M | reporter.nih.gov |
| Development of novel fetal hemoglobin inducers using targeted protein degradation | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $120,746 | April 16, 2023 | April 15, 2026 | ZHENG, SIJIN | reporter.nih.gov |
| Reproductive Care in Women with Sickle Cell Disease - Use of Secondary Data to Investigate Risk of Contraception-Related Thrombosis and the Impact of Hydroxyurea on Pregnancy Outcomes | NIH | National Heart, Lung, and Blood Institute | 2021 | $115,507 | February 10, 2020 | December 31, 2022 | OBRIEN, SARAH H | reporter.nih.gov |
| Mindfulness-based Intervention for Pain and Sleep in Adolescents and Young Adults with Sickle Cell Disease | NIH | National Institute of Nursing Research | 2025 | $114,843 | June 20, 2025 | May 31, 2027 | WI, DAHEE | reporter.nih.gov |
| Targeting Macrophage Populations to Attenuate Pulmonary Hypertension Associated with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $111,626 | August 1, 2025 | July 31, 2027 | LISK, CHRISTINA | reporter.nih.gov |
| Exploring the Mechanisms of Inflammatory Caspase Activation in Sickle Cell Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $110,737 | December 1, 2019 | June 2, 2022 | BOLIVAR-VEGA, BEATRIZ ELENA | reporter.nih.gov |
| Roles of Red Blood Cell Derived Extracellular Vesicles in Complement Activation and Thromboinflammation in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2022 | $106,486 | August 1, 2022 | February 1, 2023 | AN, RAN | reporter.nih.gov |
| Inflammatory Caspase Activation in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $103,900 | September 1, 2024 | August 31, 2026 | SALGAR, SURUCHI | reporter.nih.gov |
| Investigating the Role of Heme-Induced Complement Activation in SCD Pregnancy | NIH | National Heart, Lung, and Blood Institute | 2024 | $101,183 | September 1, 2024 | August 31, 2025 | CHAMBLISS, CHRISTOPHER | reporter.nih.gov |
| Roles of BCL11A in γ-globin repression | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $90,000 | March 1, 2020 | February 28, 2022 | LIU, NAN | reporter.nih.gov |
| The impact of diet on granulopoiesis, neutrophil function, and sickle cell disease pathology | NIH | National Heart, Lung, and Blood Institute | 2024 | $89,640 | September 1, 2024 | August 31, 2026 | MACK, ETHAN ANDREW | reporter.nih.gov |
| Examining Mortality Risk and Cause of Death among California's Newborn Screening Identified Cohort with Sickle Cell Trait | NIH | National Heart, Lung, and Blood Institute | 2021 | $89,207 | February 10, 2020 | January 31, 2023 | PAULUKONIS, SUSAN | reporter.nih.gov |
| Investigating dysregulation of hematopoietic stem cell support in sickle cell disease mesenchymal stromal cells | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $88,668 | August 1, 2023 | July 31, 2025 | CAIN, TERRI | reporter.nih.gov |
| Microbiota depletion ameliorates sickle cell induced vaso-occlusive crisis and organ damage | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $87,462 | March 16, 2022 | June 30, 2022 | LI, HUIHUI | reporter.nih.gov |
| Macrophage and Monocyte Metabolic Adaptation in Hemolysis and Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $86,522 | July 1, 2021 | June 30, 2023 | YEUDALL, SCOTT | reporter.nih.gov |
| Nationwide examination of access to comprehensive care in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $85,744 | September 1, 2025 | August 31, 2026 | RIVENBARK, JOSHUA | reporter.nih.gov |
| High-Impact Chronic Pain in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $84,231 | March 15, 2022 | August 31, 2023 | BAKSHI, NITYA | reporter.nih.gov |
| An Integrated Isothermal Nucleic Acid Test for Improved Sickle-Cell Diagnosis at the Point-of-Care | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $82,225 | July 1, 2021 | April 21, 2023 | CHANG, MEGAN MING | reporter.nih.gov |
| Anti-inflammatory actions of a novel hemin-induced electrophile in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $81,956 | May 15, 2021 | July 31, 2022 | VITTURI, DARIO A | reporter.nih.gov |
| Reactivation of Gamma Globin Expression in β-Hemoglobinopathies | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $79,166 | September 1, 2022 | August 31, 2024 | BALBIN-CUESTA, GINETTE THERESA | reporter.nih.gov |
| Biomarkers of ischemic risk in adults with sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $78,040 | December 1, 2025 | November 30, 2027 | AUMANN, MEGAN | reporter.nih.gov |
| Cerebral oxygen extraction efficiency in patients with sickle cell anemia | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $69,304 | September 1, 2024 | August 31, 2026 | SONG, ALEXANDER K | reporter.nih.gov |
| Microvascular Cerebral Blood Flow Monitoring with Diffuse Correlation Spectroscopy in Sickle Cell Anemia Children | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $64,550 | April 1, 2021 | August 31, 2022 | SATHIALINGAM, EASHANI | reporter.nih.gov |
| Investigating the mechanisms of polycomb group protein mediated fetal hemoglobin silencing | NIH | National Heart, Lung, and Blood Institute | 2025 | $54,538 | September 4, 2025 | September 3, 2029 | KAMINSKI, PAUL | reporter.nih.gov |
| Novel Endothelial and Immunologic Mechanisms of Pathophysiology in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $47,082 | September 1, 2019 | August 31, 2022 | MOLINA, PATRICK AXEL | reporter.nih.gov |
| Elucidating mechanisms of hnRNPs in fetal hemoglobin regulation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $46,036 | July 1, 2019 | June 30, 2022 | WAKABAYASHI, AOI | reporter.nih.gov |
| The Feasibility of a Medical Student Mentoring Program to Improve Transition of Care Among Adolescents with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $45,355 | September 10, 2018 | May 15, 2022 | VIOLA, ADRIENNE | reporter.nih.gov |
| Magnetic Resonance Imaging Methods to Improve Spatial Measures of Oxygen Extraction Fraction in Cerebrovascular Disease Patients | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $44,642 | April 1, 2020 | July 31, 2022 | WADDLE, SPENCER LEON | reporter.nih.gov |
| Protection against sickle cell disease nephropathy by nitrated fatty acids | NIH | National Heart, Lung, and Blood Institute | 2021 | $44,402 | August 1, 2016 | January 9, 2022 | VITTURI, DARIO A | reporter.nih.gov |
| High-resolution functional mapping of non-coding sequences regulating fetal hemoglobin | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $37,547 | March 1, 2025 | February 28, 2026 | BECERRA, BASHEER | reporter.nih.gov |
| Post-Transcriptional Regulatory Mechanisms of Fetal Hemoglobin Repression | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $33,743 | December 1, 2019 | November 30, 2021 | COYNE, STEVEN | reporter.nih.gov |
| Direct measurement of gene-environment interactions by high-throughput precision genome editing | NIH | National Institute of Environmental Health Sciences | 2021 | $30,036 | August 1, 2019 | July 31, 2022 | CHEN, SHI-AN ANDERSON | reporter.nih.gov |
| Clinical Microfluidic Assessment of Red Blood Cell Adhesion, Deformability, Cellular Hemoglobin Distribution, Cellular Density, and Blood Rheology for Curative Therapies in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $29,717 | September 20, 2019 | June 30, 2022 | GURKAN, UMUT A. | reporter.nih.gov |
| Curing Sickle Cell Disease with CRISPR-Cas9 genome editing | NIH | National Heart, Lung, and Blood Institute | 2021 | $25,000 | June 12, 2019 | May 31, 2021 | WALTERS, MARK C | reporter.nih.gov |
| Molecular determinants of fetal hemoglobin induction by hydroxyurea to treat sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2023 | $22,196 | January 16, 2021 | January 15, 2024 | DO, BRIAN TSHAO | reporter.nih.gov |
| Hemoglobin Switching Meeting | NIH | National Heart, Lung, and Blood Institute | 2025 | $10,000 | November 9, 2024 | October 31, 2025 | SANKARAN, VIJAY GANESH | reporter.nih.gov |
| 19th International Conference on Endothelin: From New Discoveries to New Treatments | NIH | National Heart, Lung, and Blood Institute | 2025 | $5,000 | September 1, 2025 | August 31, 2026 | POLLOCK, DAVID M | reporter.nih.gov |
| Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing | NIH | National Heart, Lung, and Blood Institute | 2021 | $1 | May 15, 2020 | March 31, 2022 | WALTER, ROLAND BRUNO | reporter.nih.gov |
| Contributions of biopsychosocial factors in sickle cell disease pain | NIH | National Heart, Lung, and Blood Institute | 2021 | $1 | July 15, 2020 | July 30, 2021 | ROACH, KEESHA L. | reporter.nih.gov |
| Integrating Nurse Champion Model for Group Reproductive Genetic Counseling for Sickle Cell Hemoglobinopathies into Primary Care: A Pilot Implementation Science Study | NIH | National Human Genome Research Institute | 2021 | $1 | September 21, 2021 | September 22, 2021 | JAJA, CHEEDY | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Medical College of Wisconsin | Milwaukee, WI | 12 | $32.5 million | 0 | $0 |
| Emory University | Atlanta, GA | 31 | $32.3 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 20 | $31.7 million | 0 | $0 |
| Yale University | New Haven, CT | 5 | $17.6 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 8 | $15.3 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 11 | $14.9 million | 0 | $0 |
| Research Triangle Institute | Research Triangle Park, NC | 2 | $14.6 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 10 | $14.6 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 6 | $14.2 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 3 | $13.2 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 8 | $13 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 10 | $12.7 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 11 | $12.5 million | 0 | $0 |
| Duke University | Durham, NC | 16 | $12.4 million | 0 | $0 |
| Washington University | Saint Louis, MO | 10 | $11.2 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 11 | $10.8 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 5 | $9.7 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 6 | $8 million | 0 | $0 |
| New York Blood Center | New York, NY | 5 | $7.5 million | 0 | $0 |
| The Emmes Company, LLC | Rockville, MD | 1 | $7 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 3 | $6.7 million | 0 | $0 |
| University of Cape Town | Rondebosch | 2 | $6.6 million | 0 | $0 |
| Bloodworks | Seattle, WA | 4 | $6.5 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 4 | $6.4 million | 0 | $0 |
| Ihp Therapeutics, Inc. | San Carlos, CA | 3 | $6.2 million | 0 | $0 |
| University of Florida | Gainesville, FL | 4 | $5.9 million | 0 | $0 |
| Hillhurst Biopharmaceuticals, Inc. | Montrose, CA | 3 | $5.8 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 6 | $5.8 million | 0 | $0 |
| William Marsh Rice University | Houston, TX | 4 | $5.8 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 2 | $5.8 million | 0 | $0 |
| Augusta University | Augusta, GA | 5 | $5.5 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 6 | $5.3 million | 0 | $0 |
| Hemex Health, Inc. | Portland, OR | 4 | $5.3 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 3 | $4.9 million | 0 | $0 |
| University of Tennessee Health Sci CTR | Memphis, TN | 4 | $4.9 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 2 | $4.8 million | 0 | $0 |
| Muhimbili University/ Allied HLTH Scis | Dar Es Salaam | 3 | $4.6 million | 0 | $0 |
| Biochip Labs, Inc. | Cleveland, OH | 3 | $4.4 million | 0 | $0 |
| Versiti Blood Health, Inc. | Milwaukee, WI | 5 | $4.2 million | 0 | $0 |
| University of Washington | Seattle, WA | 2 | $4.1 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 4 | $3.8 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 5 | $3.7 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 4 | $3.7 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 6 | $3.5 million | 0 | $0 |
| Howard University | Washington, DC | 2 | $3.5 million | 0 | $0 |
| Phoenicia Biosciences, Inc. | Weston, MA | 1 | $3.5 million | 0 | $0 |
| Vascular Vision Pharmaceuticals Company | Wynantskill, NY | 1 | $3.1 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 2 | $3 million | 0 | $0 |
| Icf, Inc., LLC | Fairfax, VA | 2 | $3 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 3 | $3 million | 0 | $0 |
| Boston Medical Center | Boston, MA | 2 | $2.9 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 2 | $2.8 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 1 | $2.8 million | 0 | $0 |
| Makerere University College of Health Sciences | Kampala | 4 | $2.8 million | 0 | $0 |
| Palladian Partners, Inc. | Silver Spring, MD | 1 | $2.7 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 5 | $2.7 million | 0 | $0 |
| Children's Research Institute | Washington, DC | 5 | $2.7 million | 0 | $0 |
| Brown University | Providence, RI | 1 | $2.6 million | 0 | $0 |
| Nemours Children's Hospital, Delaware | Wilmington, DE | 1 | $2.6 million | 0 | $0 |
| Strathmore University | Nairobi | 1 | $2.4 million | 0 | $0 |
| Illexcor Therapeutics, LLC | Richmond, VA | 1 | $2.4 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 6 | $2.4 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 3 | $2.4 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 6 | $2.3 million | 0 | $0 |
| University of Connecticut SCH of Med/dnt | Farmington, CT | 1 | $2.1 million | 0 | $0 |
| Rhode Island Hospital | Providence, RI | 2 | $2.1 million | 0 | $0 |
| New York University | New York, NY | 1 | $2.1 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 1 | $2 million | 0 | $0 |
| Sylvatica Biotech, Inc. | North Charleston, SC | 1 | $2 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 2 | $1.9 million | 0 | $0 |
| Emocha Mobile Health, Inc. | Owings Mills, MD | 1 | $1.9 million | 0 | $0 |
| University of Abuja | Abuja | 2 | $1.8 million | 0 | $0 |
| Midwestern University | Downers Grove, IL | 1 | $1.8 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 1 | $1.8 million | 0 | $0 |
| Feinstein Institute for Medical Research | Manhasset, NY | 1 | $1.7 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 1 | $1.7 million | 0 | $0 |
| Global Health Uganda, LTD | Kampala | 2 | $1.7 million | 0 | $0 |
| University of Connecticut | Storrs, CT | 1 | $1.6 million | 0 | $0 |
| Kwame Nkrumah University/science/tech | Kumasi | 1 | $1.4 million | 0 | $0 |
| Stanford University | Stanford, CA | 4 | $1.4 million | 0 | $0 |
| Hugo W. Moser Res Inst Kennedy Krieger | Baltimore, MD | 3 | $1.4 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 1 | $1.4 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 3 | $1.4 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 1 | $1.4 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 1 | $1.4 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 2 | $1.3 million | 0 | $0 |
| College of Health Sciences, University of Ghana | Accra | 2 | $1.3 million | 0 | $0 |
| Cleveland State University | Cleveland, OH | 1 | $1.2 million | 0 | $0 |
| Ohio State University | Columbus, OH | 2 | $1.1 million | 0 | $0 |
| Lurie Children's Hospital of Chicago | Chicago, IL | 2 | $1.1 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 1 | $1.1 million | 0 | $0 |
| University of Texas at Arlington | Arlington, TX | 1 | $1.1 million | 0 | $0 |
| Reneurogen, LLC | Elm Grove, WI | 1 | $1 million | 0 | $0 |
| New Health Sciences, Inc. | Lexington, MA | 1 | $1 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 2 | $998,907 | 0 | $0 |
| University of California at Davis | Davis, CA | 1 | $925,439 | 0 | $0 |
| College of Health Scis Univ of Zimbabwe | Harare | 1 | $904,461 | 0 | $0 |
| Univ of Sciences, Tech & Tech of Bamako | Bamako | 1 | $892,318 | 0 | $0 |
| University of South Florida | Tampa, FL | 2 | $857,419 | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 1 | $854,053 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 199 | $112,029,306 | 0 | $0 |
| 2024 | 207 | $111,900,962 | 0 | $0 |
| 2023 | 206 | $132,305,096 | 0 | $0 |
| 2022 | 187 | $102,604,405 | 0 | $0 |
| 2021 | 199 | $94,822,236 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.